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ABSTRACT 
 
OPTIMIZATION OF CALCIUM ALUMINATE FOR USE AS A BONE SCAFFOLD 
MATERIAL THROUGH PHYSICAL AND CHEMICAL SURFACE MODIFICATION 
 
 
 
By 
Rachelle Nicole Palchesko 
February 2011 
 
Dissertation supervised by Professor Ellen S. Gawalt 
 Calcium aluminates were tested as biomaterials and show promise as bone 
scaffolds. Initial concerns of biocompatibility led the field to focus on calcium 
phosphates. Here, the work focused on improving the biocompatibility and creating an 
optimized calcium aluminate biomaterial. To accomplish this, the physical and interfacial 
properties of the material were varied. The physical properties of the calcium aluminate 
were varied through the room temperature casting procedure and five different mixtures 
were created and evaluated for mechanical strength and biotolerability. The results 
showed that the optimal mixture had an average pore size of approximately 100µm and 
that autoclaving the material increased the strength and therefore was the best 
sterilization method for all studies.  Following optimization of the physical properties, the 
cell adhesion peptide KRSR was immobilized onto the surface to increase specific 
 v 
osteoblast adhesion and RGD was immobilized as a non-cell specific peptide control. It 
was determined that KRSR preferentially increased osteoblast over fibroblast adhesion 
and increased osteoblast adhesion compared to unmodified and RGD modified calcium 
aluminate which is important for a bone scaffold material.  Biofilm formation and 
implant associated infections are still a significant problem despite advancements in 
sterile techniques in operating rooms.  To mitigate bacterial attachment, vancomycin and 
ampicillin were successfully immobilized on the surface through both covalent 
attachment and adsorption.  Vancomycin remained active after autoclaving and was 
extremely effective at inhibiting bacterial growth when compared to unmodified calcium 
aluminate and the control antibiotic dosage.  Finally, both KRSR and vancomycin were 
simultaneously immobilized utilizing three different attachment schemes.  A double 
immobilization scheme that allowed for antibiotic activity and increased osteoblast 
attachment was found producing an optimized calcium aluminate material for use as a 
bone scaffold. 
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Chapter 1 : Background 
1.1 Introduction 
 There are approximately 1.5 million bone-graft surgeries annually in the United 
States
1, 2
 and more than 2.2 million worldwide.
3
 Autografts and allografts are currently 
the two most common methods of bone replacement making up 90% of the bone grafts 
used with only approximately 10% being from synthetic sources.
4
  The biological, 
chemical and mechanical requirements of a successful bone graft along with the failure of 
allografts and synthetic substitutes to meet these requirements are part of the reason that 
the autograft is still the gold standard among bone replacements.  However, with the 
advancements in biomaterials, tissue engineering, and surgical techniques, current 
research gives hope that there will be a synthetic bone graft substitute that is biologically 
comparable to the autograft in the near future. 
 
1.2 Requirements for Bone Substitutes 
The mechanical strength, chemical and biological activity are all important factors 
in determining the requirements for a bone graft substitute. Synthetic biomaterials must 
be strong, resist wear and corrosion, be non-toxic, and favor cell attachment, proliferation 
and differentiation.
5-7
 
The strength of the material must have similar tensile strength, elastic modulus, 
and compressive strength to the cortical or cancellous bone that it is going to replace.  
This is very important, because materials involved in load bearing applications will have 
to be much stronger than those involved in craniofacial applications that are non-load 
2 
 
bearing.
3, 8-10
 Similar elastic modulus and toughness are important in avoiding stress 
shielding and to prevent cyclic loading fatigue fracture.
10
 
 
 Testing direction Compressive 
strength (MPa) 
Tensile strength 
(MPa) 
Young’s 
Modulus (GPa) 
Cortical Bone Longitudinal 193 133-150 17-25 
Cortical Bone Transverse 133 50 12 
Cancellous  Bone Longitudinal 3.6-9.3 ---- 0.26-0.90 
Cancellous Bone Transverse 0.6-4.9 ---- 0.01-0.40 
Hydroxyapatite n/a ---- 9-120 80-117 
Collagen Longitudinal ---- 100 1.5 
Table 1-1:Table of mechanical requirements for cancellous and cortical bone compared 
to synthetic materials.
11
 
 
As a result, chemical reactivity of the biomaterial should be limited and include 
desired bioerodible or biodegradable reactions.  The material provides a temporary 
framework allowing for the bone regeneration and repair. Therefore the material should 
degrade, but not too quickly in order to give the tissue time to repair. 
Although the mechanical requirements and the chemical reactivity are important, 
the biological requirements for the material are the most important.  An optimal bone 
graft material should be osteoconductive, osteoinductive, osteogenic, and 
osteintegrative.
3, 9, 10, 12
  Osteoconductivity is the ability of a biomaterial to support the 
growth and viability of osteoblasts.  Osteoblast cells are necessary for bone formation and 
a surface should support their growth and attachment in order to be considered 
osteoconductive.
3, 9, 10, 12
  Osteoinductivity is the ability of the material to induce 
mesenchymal stem cells to differentiate into osteoblasts, osteoclasts, etc.
3, 9, 10, 12
 There 
are few mature osteoblasts present in the human body and therefore it is advantageous for 
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a biomaterial to be able to induce mesenchymal stem cells that are present in bone tissue 
to differentiate into mature osteoblasts in order to regenerate bone tissue. Biomaterials 
should also allow for living cells to proliferate within the graft for tissue to regenerate 
and for bone to form in place of the graft, this is known as osteogensis.
3, 9, 10, 12
 Finally 
osteointegration is the ability of the surfaces of the bone and the graft to bind to one 
another. 
3, 9, 10, 12
 Without proper binding between the bone and graft, the implant will 
dislocate and bone regeneration will not occur. 
The osteoinductive and osteoconductive properties of a biomaterial are directly 
influenced by pore size, pore connectivity and the overall porosity of the material.
6
 The 
porosity of natural bone varies with bone type in a range of  3-90% porosity with 
individual pores up to 1 mm in diameter.
13-16
 Pores are tunnel like holes that go from the 
surface to the bulk of a material either partially or completely. These pores can connect 
inside the bulk to the material to create a network that allows for the flow of molecules 
from the outside of the material in and vice versa. In a surface without pores, there is 
often attachment of the cells on the surface but not at the center of the implant.  The 
center of the implant then experiences necrosis and failure.  Therefore, the scaffold must 
allow for the transfer of nutrients and cell migration into the scaffold meaning that the 
material should be porous.
6
  Vascularization is important if bone is to form and grow into 
an implant which also requires a porous material.  This vascularization requires blood 
supply which provides the calcium and phosphorous that are necessary for bone 
formation.
17, 18
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1.3 Current Graft/Implant Materials 
1.3.1 Autografts and Allografts 
The only current graft that supports osteoconductivity, osteoinductivity, 
osteogenicity, and osteintegration is the autograft.  An autograft, a piece of bone taken 
from the patient’s own body, is the most desirable type of replacement because the tissue 
comes from the patient and therefore would not elicit an immune response. Autografts 
also possess all the characteristics necessary for bone growth.
4
 There are great 
disadvantages to autografts because they require a second surgery site for the patient 
which puts more strain on the body, causing possible cell death at the donor site. 
Additionally, the size of the graft needed could be too large for an autograft to be 
feasible.
19
 Allografts are bone grafts from deceased donors and can be used when the 
graft size exceeds that of an available autograft and possess three of the important 
biological requirements, osteoconductivity, osteoinductivity, and osteointegration.  
However,  they are not osteogenic because they lack living tissue.
4
  A major disadvantage 
of the allograft is the introduction of possible pathogenic transmission.
19
 
 
1.3.2 Metal Replacements 
Synthetic bone scaffold and replacement material research is receiving increasing 
attention although those currently available only allow for osteoconduction and 
osteointegration.  Out of the 10% of synthetic bone substitutes used, the majority are 
metal replacements which are mainly used when the defect in the bone is of critical size 
and/or load bearing.  The most common metals used are titanium and its alloy Ti-6Al-
4V.
7, 20
 It has been shown in the literature that on rough titanium surfaces osteoblasts 
5 
 
exhibit increased adhesion, differentiation, matrix production and calcification and there 
is a reduction of osteoclasts.
21
  Also, the INFuse Graft that is approved by the FDA for 
bone grafting, consists of a titanium or titanium alloy rod with a collagen sponge and 
bone morphogenetic protein-2 (BMP-2). Other common metal implant materials are 
stainless steels (usually 316L), Co-Cr alloys and more recently tantalum.
5, 9, 11, 12, 22-24
 
 
1.3.3 Ceramics, Glasses, Etc 
Although metals are the most common synthetic substitutes for large bone defect 
filling, there are other synthetic options available such as scaffolds, when the defects are 
smaller and/or not load bearing in nature.  Scaffolds of calcium phosphates and apatites 
(Vitoss) and polymer composites (Cortoss) that include tricalcium phosphate, 
hydroxyapatite and coralline hydroxyapatite are desirable because they mimic the real 
crystalline composition of bone which is calcium hydroxyl apatite.
11, 12, 23, 25-28
  Bioactive 
glass (Bioglass), demineralized bone matrix collagen, calcium sulfate (filler), calcium 
carbonate (filler), alumina, bovine derived bone mineral (Bio-oss) and bioactive ceramics 
(glass and zirconia) are less common but have all been used as bone void fillers or bone 
graft expanders in conjunction with autografts and allografts.
3, 10, 12, 22, 29
 
 
1.4 Failure of Synthetic Implants 
1.4.1 Biological Failure 
An optimal bone replacement material would be osteogenic, osteoconductive, 
osteoinductive, and osteointegrative; however, all replacements except for native tissue 
lack at least one of these four major requirements, leading to some type of implant failure 
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such as delayed union, nonunion, and malunions to name a few.
3, 30
  One of the major 
shortcomings of synthetic replacement materials is their lack of osteogenicity and 
osteoinductivity.
10
  Current synthetic materials and allografts do not contain any living 
cells and therefore lack the ability to be completely osteogenic.  Often synthetic materials 
are not osteointegrative which leads to loosening of the implant from the surrounding 
bone.  Some materials such as bioinert metals, like titanium and cobalt/chromium alloys, 
and some ceramics, do not allow for osteoconductivity leading to fibrous tissue formation 
around the implant ultimately causing implant failure.
5, 9, 31
  Metal replacements do not 
contain pores which allow for cell migration, nutrient transfer, and vascularization and 
are necessary to eliminate necrosis at the center of the implant or tissue surrounding the 
implant. Titanium, for example, does not stimulate a high amount of bone formation and 
can lead to the formation of soft fibrous tissue that leads to complications in bone wound 
healing.
32
 
Fibrous tissue formation on any bone replacement begins with blood coagulation 
which leads to the production of fibrin and the migration of white blood cells.
5
  
Macrophages then colonize the implant inducing foreign body giant cells which recruit 
fibroblasts that then wall off the implant.
5
  The release of metal debris can also lead to 
production of cytokines which also produce foreign body giant cells and stimulate the 
formation of fibrous tissue.
8
  These metal particles bind to specific serum proteins and 
induce an immunological response that leads to cell toxicity and cell lysis as 
macrophages phagocytose the metal particles which leads to their death.
9, 22
  As the 
macrophages die, they release the metal ions into an acidic environment which causes 
more cells to lyse and the cycle continues.
22
   It has been shown that exposure of bone to 
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cobalt/chromium alloys causes a reduction in osteoblast proliferation due to the toxicity 
of the metal release.
9
  Hydroxyapatite and some polymers have also shown low or 
unpredictable resorption in the physiological environment and the implants lead to an 
inflammatory response and foreign body reaction like metals and lead to fibrous tissue 
formation.  One failure that is specific to the FDA approved INFuse graft is the formation 
of too much bone in an inappropriate location due to the BMP-2.
31, 33
 
Another common cause of implant/graft failure is infection.
34-42
  Bacteria adhere 
to the surface of the implant shortly before or after implantation.  The bacteria begin to 
form biofilms which require high systemic doses of antibiotics and are often completely 
resistant to antibiotics due to their extra cellular polysaccharide matrix.
36, 43-49
 If the 
infection cannot be eradicated with systemic antibiotics, the implant must be removed.  
This requires not only a second surgery to remove the implant, but a spacer must be put 
in its place.  The wound is then treated with antibiotics and allowed to heal.
35, 37, 42
 After a 
prolonged healing period a third surgery is then necessary to remove the spacer and 
replace the implant. 
 
1.4.2 Mechanical Failure 
Although the  inability of synthetic implants to be osteoinductive, 
osteointegrative, and/or osteogenic impairs the current materials’ role in regeneration of 
new bone, the most common causes of bone implant failure are due to mechanical 
reasons.  Metal corrosion within the physiological environment can lead to decreased 
strength and limits the fatigue life of the implant causing mechanical failure and implant 
loosening.
7, 9, 21
   Metal corrosion is caused by oxidation/reduction reactions that occur on 
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the surface of the implant.
8
 Some of the metals used such as titanium and its alloys, and 
cobalt/chromium alloys are thought to be corrosion resistant, however at the bone/implant 
interface, crevice corrosion and stress corrosion can occur in load-bearing implants.
8
 
A mechanism of mechanical failure common to metals, ceramics, glasses etc. is 
mechanical mismatch.
9
   When the mechanical properties of the materials are different 
than that of the bone it is replacing, stress shielding occurs.
9, 18
  The bone surrounding the 
implant will be insufficiently loaded which leads to bone resorption, implant migration, 
aseptic loosening, and fractures.
9
  Specifically, a mismatch of Young’s Modulus can 
cause implant loosening.
9
  Young’s modulus for bone is between 10 and 30 GPa, whereas 
for metallic materials it is around 110GPa for titanium and 230GPa for cobalt chromium 
alloys.
9
  This type of failure is quite common and has Wolff’s Law to describe such 
failures; when a material is stiffer than the cortical bone, the bone is subjected to a 
reduced mechanical environment and the bone resorbs.
24
 Although metals exhibit stress 
shielding they are sufficiently strong enough to support weight in load bearing 
applications which reduces implant fracture.   
Ceramics, polymers and glasses in load bearing applications often fracture due to 
the materials’ inability to sustain the mechanical forces placed on the implant.9, 23 
Ceramics such as hydroxyapatite and tricalcium phosphate are weak and brittle (i.e. rigid 
and inflexible) (Table 1-1).
3, 10, 23
  They are slow to resorb which can lead to detachment 
and fracture if too much weight is placed on them.
9, 23
 For this reason, these ceramics are 
often not used on their own, but rather used in conjunction with an autograft.
24
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1.5 Current Research Directions for Materials Design 
1.5.1 Metallic Materials 
 Metals possess the strength necessary for many load bearing applications, but 
because they are not biodegradable, nor do they allow for cell ingrowth, they often lead 
to stress-shielding and fibrous tissue formation as mentioned earlier.  Current research is 
focusing on the fabrication of porous metals such as titanium, stainless steel, and Co-Cr 
alloys to allow for cell growth into the material.
9
  By inducing pores into the metal 
structure, there is a possibility that blood vessels and cells would be able to grow into the 
implant which is necessary for nutrient transport and also bone regeneration.  This could 
also improve the mechanical property mismatch. 
Metals that are currently not clinically being used as bone replacements such as 
nitinol are being investigated as possible materials for bone replacements.  Nitinol is 
desirable because of its excellent elastic and shape memory properties.
9
  Porous nitinol is 
also being fabricated to allow for more desirable mechanical and biological properties. 
“New” formulations of alloys in the titanium and Co-Cr families have been manufactured 
to determine their ability to allow for better biological properties.
8
 
Surface modification is being used on various metals such as nitinol to reduce 
corrosion and thereby reduce the amount of metal ions and metal debris that is released 
into the body to eliminate cytotoxic and genotoxic effects.
50
  These modifications will 
increase the number of metals that will be available for use by eliminating toxic effects 
due to ion and debris release.  
Even with research to increase their biological properties, current metals still 
exhibit the mechanical failure associated with stress shielding.  For this reason, there is a 
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new focus on “bioresorbable/biodegradable” metals such as magnesium.51-54 These 
metals provide temporary strength for support and a framework for bone regeneration 
with the ability to degrade within the body and allow for bone healing and regeneration 
while possibly eliminating the effects of stress shielding.   
 
1.5.2 Composite Materials 
 Composite materials aim to combine the most desirable properties from different 
materials into an optimal graft whose function is superior to that of its individual 
components.  Composites consisting of hydroxyapatite and other bioactive ceramic 
coatings (calcium silicate) on metals and polymers have shown promise by providing the 
bioactive properties of the coating with enhanced mechanical properties of the underlying 
core.
8, 23, 55, 56
 
 Chen et al. fabricated a composite material consisting of a porous titanium core 
with a calcium ion coating.
43
 The coating was found to induce apatite formation on the 
surface of the material when immersed in simulated body fluid.
43
  Another group 
combined the biodegradable nature of the magnesium alloy with a calcium phosphate 
coating to try and reduce stress shielding effects while enhancing the biological 
properties of the scaffold.
51
 The data showed an increase in the bioactivity of the 
composite material compared to control magnesium and control titanium implants.
51
  
Moreau et al created a calcium phosphate cement/chitosan composite and saw increased 
osteoconductivity and osteoinductivity of the composite material when compared to the 
calcium phosphate cement alone.
57
    These findings indicate composite materials may be 
more beneficial for bone grafting than single component materials. 
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1.5.3 Biomolecule Functionalization 
Current  and prospective biomaterials are being improved upon by 
functionalization and modification with various drugs and biomolecules.
20, 31-34, 48, 58-63
  
The goal of drug modifications is to reduce implant failure that is caused by 
inflammation, infection, and other adverse tissue responses while modification with 
biomolecules is used to increase the bioactivity of biomaterials by increasing cell 
attachment and proliferation.   
Numerous papers focus on surface and bulk modification of current biomaterials 
with antibiotic coatings that could reduce implant failure due to infection.
58, 64, 65
 Silver 
coatings, or attachment of antibiotics to the surface of the material would kill any bacteria 
that attempt to attach to the surface of the implant before infection can occur and cause 
implant failure.  This would be beneficial, but improving the biological properties of the 
material with biomolecules could be more important than antibiotic coatings because of 
the low rate of failure due to infection. 
 The release of drugs and various growth factors such as TGF-B, VEGF, BMP-2, 
FGF-2, melatonin and heparin are being investigated to determine their ability to improve 
current bone grafts.
59, 62, 66
   Sequential delivery of VEGF and BMP-2 from polymeric 
materials has been shown to induce bone formation and vascularization.
59
  The delivery 
was used to grow bone in a location where there was previously no bone tissue and also 
used to close a 5 mm defect in rat femurs.
59
  As mentioned earlier, BMP-2 is already used 
in conjunction with a collagen sponge and a titanium rod in the INFuse graft system.  
Modification with and addition or injection of BMP-2 with many graft materials could 
increase their biological success but delivery needs to be localized to reduce unwanted or 
12 
 
excess bone formation.  Heparin modifications are being used to possibly reduce blood 
coagulation which would reduce the foreign body response seen with synthetic 
implants.
66
  Takechi et al reported newly formed bone was seen around titanium implants 
that had been modified with melatonin and FGF-2 whereas no new bone formation was 
seen around control titanium implants that had not been modified.
62
  These are some of 
the many growth factors that have been shown in the literature to increase bone 
formation.  The next necessary step is narrowing down which combination of growth 
factors gives the best result without unwanted or out of control bone growth. 
Cell adhesion peptides, specifically, RGD (arg-gly-asp), have received a lot of 
attention in the literature, even more so than growth factors.
19, 60, 61, 63, 67, 68
  RGD was 
chosen because it is a sequence domain that is present in many extracellular matrix 
proteins including fibronectin whose main function is to mediate the adhesion of cells.
61, 
68
  Studies have shown that this peptide can increase the attachment of mesenchymal stem 
cells to different substrates (hydroxyapatite, titanium, polymer scaffolds) but not the 
spreading of the cells.
19, 61, 68
 Cell spreading is important for cell survival and cell 
differentiation into osteoblasts which are necessary for bone formation and 
regeneration.
61, 68
For this reason, the focus has shifted towards a different peptide-one 
that binds to transmembrane proteoglycans and could improve cell attachment and 
spreading.
32
  An example of this type of peptide is the KRSR peptide. 
 Sawyer et al compared the KRSR peptide to the RGD peptide modified 
hydroxyapatite. Although they did not find and increase the mesenchymal cell 
attachment, they found that cell spreading was increased.
61
  This indicated that the cells 
were interacting with the proteoglycan binding peptide through the cell surface 
13 
 
receptors.
61
Balasundaram et al investigated the KRSR peptide on the titanium surface and 
found that immobilizing the peptide on the surface increased osteoblast adhesion in 
vitro.
32
 
 Cell adhesion peptides are of increasing interest because bone formation at the 
interface of a bone implant occurs as a result of competition between bone regeneration 
and fibrous tissue formation only when bone regeneration is dominant.
5
  It is therefore 
necessary to try and increase the bone regeneration while limiting the fibrous tissue 
formation at the interface of the implant with existing bone.  An optimal biomaterial 
would allow for the preferential attachment of osteoblasts over fibroblasts which would 
increase the regeneration of bone in comparison to the fibrous tissue formation.  
 
1.5.4 Tissue Engineering 
 Modification of current materials and design of new materials offer promise in 
creating a bone graft substitute that may be comparable to the allograft, however in order 
to be comparable to the autograft and allow for osteogenic activity, a shift towards tissue 
engineering can be seen in the literature.  Tissue engineering involving the implantation 
of cells, usually stem cells, with biomaterials, or cells encapsulated in biomaterials will 
provide living cells to aid in increasing osteogenic activity.
29, 69
  For example, platelet-
rich plasma is being used in concert with many biomaterials in animal models to look 
into its possible effects in increasing bone and vessel formation.
70
  Some of these 
techniques are also being employed with allografts to increase their success rate and 
osteogenicity.   
14 
 
 Currently, there is a trend towards using a patient’s own cells instead of allogenic 
or xenogenic stem cells in tissue engineering applications.  A patient’s cells are harvested 
and placed in bioreactors to allow for the proliferation of the cells.  Once the cells have 
proliferated, they can then be implanted into a bone defect either alone or in combination 
with a biomaterial to increase the success of the graft.
11
   In the future, the tissue 
engineering community hopes to be able to use the patient’s body as the bioreactor 
environment to allow for the proliferation of cells.  At this point in time, the harvesting of 
cells and use of a bioreactor would require more time than current biomaterials and tissue 
engineering approaches and therefore could only be used in non-emergency/trauma 
situations. 
 
1.6 Literature Summary 
 The autograft remains the gold-standard graft in bone defect filling because of its 
osteogenic character.  Current biomaterials do not meet the requirements in order to 
replace the autograft as the most common and desirable material.  Synthetic materials fail 
to meet either the mechanical and/or the biological standards necessary to replace the 
autograft.   Current research in the biomaterial and tissue engineering fields have made 
great progress toward finding a suitable and comparable replacement but there are still 
many advancements to be made before any synthetic material will take the place of the 
autograft. 
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1.7 Experimental Approach 
Synthetic replacements and scaffolds strive to meet several criteria: 
osteoconductivity, osteoinductivity, osteogenicity, and osteointegration. Meeting all of 
these criteria is a daunting task and though some synthetic materials meet some of the 
criteria this goal has not yet been reached.
3, 9, 10, 12
   This project aims to improve the 
osteoconductive and antibacterial properties of the calcium aluminate material for use as 
a bone scaffold material through physical and chemical surface modification of the 
material.  The physical properties were optimized by varying the average pore size of the 
material through the casting process. Different mixtures were evaluated for strength, 
phase composition, biodegradability and cell adhesion.  The surface of the optimal 
mixture was then chemically modified with cell adhesion peptides to increase the 
osteoblast adhesion and decrease fibrous tissue formation.  The surface was then 
modified with antibiotics to reduce bacterial adhesion and growth on the material.  
Finally, two biomolecules, one cell adhesion peptide (KRSR) and one antibiotic 
(vancomycin) were simultaneously immobilized on the surface of calcium aluminate and 
remain active to produce a surface that both increases osteoblast adhesion and decreases 
bacterial growth. This study does not address the osteogenic, osteoinductive or 
osteointegrative properties of the calcium aluminate at this time.   
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Chapter 2 : Physical Optimization of Calcium Aluminate 
2.1 Introduction 
Calcium aluminates were utilized as scaffolds and showed promise in initial 
studies
1-5
 but they have since been over-looked because of concern for their 
biocompatibility.  However, in vivo studies have shown that the calcium aluminates do 
not elicit an inflammatory response proving biotolerability and indicating the material 
may be a promising bone scaffold, particularly with chemical modifications to improve 
its biocompatibility.
1-9
  Calcium aluminates have been re-examined in this project 
because the aggregates are naturally porous, non-toxic, and can be easily cast into 
predesigned shapes when hydrated at room temperature. 
Pores are necessary for nutrient transport between an implant surface and its 
physiological environment as well as for cell attachment. However when pores become 
too large a biomaterial will lose mechanical integrity and become either brittle (i.e. rigid 
and inflexible) or weak, or both.   It is important to optimize the pore size of a biomaterial 
to allow for increased nutrient transport and cell attachment, as well as strength. It is also 
important to optimize the process of forming desired shapes of a biomaterial.  Some 
implants must first be cast into bulk shapes and then machined to match the size of the 
defect which can lead to a poor fit of the implant which will eventually cause implant 
loosening and failure.  This is due to the high temperatures that are required to cast the 
material and/or the lack of necessary facilities in the hospital to be able to cast the 
implants.   Calcium aluminate has the advantage that it is easily cast into any desired 
shaped through a room temperature hydration reaction which allows for custom shaped 
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implants that are made quickly and easily and may reduce the incidence of poor implant 
fit.  
The hydration reaction of calcium aluminate (CA) during the casting procedure 
occurs in a three-step mechanism.
10
 Briefly, the surface of the calcium aluminate is 
hydroxylated and then begins to dissolve  until the saturation limit has been reached 
(dissolution).
10
  After the dissolution step, the nuclei continue to grow in critical size and 
quantity, which is known as the nucleation phase.
10
 Finally, the precipitation phase 
occurs in which the hydrates precipitate out of the solution.
10
 This three-step mechanism 
continues until all of dissolved CA has been reprecipitated.
10
  During this hydration 
process the hydrated phases bind together and interlock with each other and the 
unhydrated phases to form the cast shape and increase the mechanical strength of the 
material.
10
 
The strength of the material can also be influenced by the particle size of the 
starting aggregates.  A smaller aggregate particle size would allow for increased 
hydration, thus increasing the strength of the material.  This would decrease the average 
pore size due to tighter particle packing.  A larger aggregate particle size would decrease 
hydration, decreasing overall strength, but increase the average pore size. Combining 
large and small aggregate particle sizes allows for particle packing that creates a range of 
different pore sizes within the same material (Figure 2-1). 
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Figure 2-1: Schematic diagram of different types of particle packing.  Aggregates are 
separated by size and then mixed in fixed ratios to produce mixtures with different 
average pore sizes. 
 
In order to optimize the physical properties of CA for use as a biomaterial, the 
pore size of the calcium aluminate was varied.  This was accomplished through the 
hydration process by changing the percent composition of different sized starting 
aggregates and creating five different mixtures.  The different mixtures were then 
subjected to four different heat treatments.  All mixtures were then evaluated for average 
pore size, strength, phases present, biodegradability and cell attachment. 
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2.2 Materials and Methods 
2.2.1 Materials 
Calcium aluminate aggregates were supplied by Westmoreland Advanced 
Materials.  NIH 3T3 Fibroblasts (CCL-92) were purchased from ATCC.  Dulbecco’s 
Modified Eagle Media (DMEM/High glucose, Hyclone), phosphate buffered saline (PBS, 
- calcium and magnesium, Hyclone) fetal bovine serum and penicillin/strepavidin were 
purchased from Fisher.  Unless otherwise noted all chemicals were used as received.   
 
2.2.2 Pore Size Measurement 
Calcium aluminate bars were prepared by a room temperature (20 ºC) cast of 
different sized calcium aluminate aggregates with phases CaAl2O4 and CaAl4O7.   Four 
different aggregate sizes were used in our casting process -10 + 30, -30 + 60, -60, and      
-325.  The larger mesh numbers indicate smaller aggregates with -325 being fine powder-
like cement.  Five different combinations of the aggregates were cast with compositions 
of: A: 50% -325 and 25% each of -30 + 60 and -60; B: 25% of each of the four sizes; C: 
33% each of -10 + 30, -30+60 and -60; D: 50% each of -10 + 30 and -30 + 60; and E: 
100% -10 + 30. The aggregates were dry mixed at room temperature to ensure complete 
particle distribution.  After dry mixing, doubly-distilled H2O (ddH2O) was mixed in and 
the cement paste was allowed to sit for 20 minutes at room temperature to thicken.  Upon 
thickening, the cement was poured into a mold of a 1 X 1 X 12 inch bar and allowed to 
sit overnight at room temperature (20 º C).   
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  The cast CA bars were then heat treated in one of four ways: 20 ºC (room 
temperature control), 120 ºC, 650 ºC, or autoclaved at 121 ºC and 18 psi of steam 
(standard sterilization procedure for dry materials).  
 
 
Figure 2-2: Examples of pore diameter measured by optical microscopy. On the left 
there is an example of a larger pore, and on the right is an example of the same size area 
with multiple smaller pores.  The scale bars show how the diameter of each pore was 
measured. 
 
CA mixtures were visualized by optical microscopy on an Axioskop2 (10x 
magnification) and measured using the Axiovision 4 software.  A two-way ANOVA 
analysis with Bonferroni post hoc test (p<0.05) was then used to determine any statistical 
differences in pore size due to mixture composition or heat treatment. Figure 2-2shows 
examples of pores on the CA surface and their diameters. 
 
2.2.3 Mercury Porosimetry 
Ten 8 mm disks each of Mixtures A, B, and C with no heat treatment and 
Mixtures Aauto, Bauto, and Cauto were sent to Delta Analytical Instruments Inc. in North 
Huntingdon, Pennsylvania for mercury porosimetry analysis. 
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2.2.4 Strength Testing 
Mixtures A, B and C were cast at room temperature as described above in 1 x 1 x 
12 inch bars.  A total of 16 bars of each mixture were cast and 4 of each mixture were 
then subjected to one of the four heat treatments (a total of 4 bars of each mixture per 
heat treatment).  The bars were then subjected to a standard four point bend test to 
calculate the modulus of rupture.  A 1 in
3
 cube was then cut from each bar for a total of 4 
data points for each mixture at each heat treatment to subject to a standard cold crushing 
test.  All data was then analyzed by two-way ANOVA with Bonferroni post hoc test 
(p<0.05) to determine if the mixture composition or heat treatment had an effect on the 
strength of the material. 
 
2.2.5 Powder X-Ray Diffraction 
To determine the CA phases present in the CA Mixtures A, B and C that had been 
subjected to the four different heat treatments, the samples were analyzed using Powder 
X-ray Diffraction (PXRD) on an X’Pert PANalytical Pro. The samples were scanned 
from 5 to 70º 2θ with a time per step of 720.090 seconds at a scan speed of 0.002947 º 
per second for a total data collection time of 6 hours. The collected patterns were 
analyzed using X’Pert HighScore Plus software by matching all peaks in the collected 
patterns to reference patterns in the database. 
 
2.2.6 Biodegradability 
Ten disks each of Mixtures A, B, and C were soaked in ddH2O overnight and 
allowed to dry at room temperature to ensure they were fully hydrated.  They were then 
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weighed and placed into 24 well plates and two milliliters of PBS was added to each 
well.  The well-plates were placed on a shelf at room temperature.  Weekly, samples were 
removed, dried in a 120 ºC oven for 3 hours until all liquid had evaporated and then 
weighed to determine any change in mass.  Samples were then placed back into the well 
plates and two milliliters of fresh PBS was added.  The change in mass was observed for 
26 weeks. 
 
2.2.7 Fibroblast Attachment 
NIH Swiss Albino mouse 3T3 fibroblasts were cultured until confluent and 
diluted to a concentration of 10,000 cells per milliliter of media (DMEM/High Glucose, 
10% FBS, 1% strepavidin/penicillin).  Three of each type of substrate (Mixtures A, B and 
C) per time point were placed in a 48-well plate and 1mL of cells was added to each well.  
After 1, 4, and 7 days, the number of live cells was determined using the 
Live/Dead/Viability/Cytotoxicity Assay Kit from Invitrogen by counting the number of 
live (green) versus dead (red) cells.  Five spots on each sample with an area of 0.6 mm
2
 
were imaged under 10 x magnification using the Axioskop2.  Three separate trials were 
completed with a total of 9 samples of each type with a total of 45 views for each sample 
type at each time point.  Statistical analysis of the average number of live cells per view 
was done using Origin 8.0 using a one-way ANOVA with a Bonferroni post hoc test 
(p<0.05).   
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2.3 Results 
2.3.1 Pore Size Control 
In order to determine the optimal pore size for cell growth on this material, the 
calcium aluminate (CA) mixture composition was varied. This was achieved by changing 
the ratios of the CA aggregates during the room temperature casting process.  Four 
different aggregate sizes were used in our casting process -10 + 30, -30 + 60, -60, and -
325.  The larger mesh numbers indicate smaller aggregates with -325 being fine powder-
like cement.  Five different combinations of the aggregates were cast with compositions 
of: A: 50% -325 and 25% each of -30 + 60 and -60; B: 25% of each of the four sizes; C: 
33% each of -10 + 30, -30+60 and -60; D: 50% each of -10 + 30 and -30 + 60; and E: 
100% -10 + 30.  The CA aggregates were dry mixed and then cast into a bar mold with 
ddH2O.  The cast CA bars were then heat treated in one of four ways: 20 ºC (room 
temperature control), 120 ºC (for 48 hours), 650 ºC (6 hours), or autoclaved at 121 ºC and 
18 psi of steam (1 hour). Following the heat treatments, the average diameter of the pores 
within the different CA mixtures was visualized by optical microscopy on an Axioskop2 
(10 x magnification) and measured using the Axiovision 4 software (an example of pore 
sizes shown in Figure 2-2). 
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Table 2-1: Table showing the percentage of each CA aggregate present in each mixture 
and the average pore size of that composition. 
 
The average pore diameters ranged from approximately 100µm to 300µm. The 
average pore diameter over the four heat treatments for the CA was: Mixture A = 101.68 
± 115.60µm, Mixture B = 148.90 ± 151.05 µm, Mixture C = 210.09 ± 186.76 µm, 
Mixture D = 258.68 ± 174.26 µm, and finally Mixture E = 288.28 ± 176.95µm (Table 
2-1).Two-way ANOVA analysis with Bonferroni post hoc test (p<0.05) determined that 
all mixtures had statistically significantly different pore sizes from one another, except 
there was no difference between Mixtures D and E.  Statistical analysis also determined 
that the heat treatments did not affect the pore size of the material. The Mixtures D and E, 
with the two largest pore sizes, were determined to be unsuitable for further investigation 
because of their visible lack of mechanical strength.   
 
2.3.2 Mercury Porosimetry 
Mercury porosimetry data was used to determine the overall pore volume of 
Mixtures A-C with no heat treatment and that had been autoclaved.  Mixture A had 
27.39% porosity and Mixture Aauto had 20.36% porosity.  Mixture B had 37.25% porosity 
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and Mixture Bauto 28.05% porosity.  Mixture C had 39.77% porosity and Mixture Cauto 
had 31.75% porosity. These results indicated that the larger the average pore size of the 
material, the larger the average pore volume. 
 
2.3.3 Strength Testing 
 
Table 2-2: Strength data for different mixtures and heat treatments of cast CA. 
None=samples which were cast at room temperature and received no additional heat 
treatments. Two-way ANOVA with Bonferroni post hoc test, p<0.05, i=greater modulus 
of rupture, ii=greater cold crushing strength, iii=decreases modulus of rupture and cold–
crushing strength, iv=increases modulus of rupture). 
 
Two-way ANOVA analysis (Bonferroni post hoc test, p<0.05) was used to 
analyze the cold crushing and modulus of rupture strength testing data (Table 2-2).  The 
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results showed that heat treating the samples at 650 ºC after casting, statistically 
significantly decreased the cold crushing strength and the modulus of rupture of all 
mixtures.  Autoclaving the mixtures after casting statistically significantly increased the 
modulus of rupture of all mixtures.  Mixtures A and B were statistically significantly 
stronger than Mixture C in the modulus of rupture test and Mixture A was stronger than 
Mixtures B and C in the cold crushing test.  
 
2.3.4 Powder X-Ray Diffraction 
The CA aggregates of all sizes, for example -10 + 30 and -60, used in this project 
were produced from the sintering of starting materials CaCO3 and Al2O3.  These 
aggregates were in two different phases CaAl2O4 and CaAl4O7. The two phases were then 
mixed with water during the hydration process and new phases of hydrated calcium 
aluminate were precipitated forming the bonds that make calcium aluminate castable.   
To determine the new phases present in the hydrated CA, Mixtures A, B, and C 
that had been subjected to four different heat treatments were analyzed using Powder X-
Ray Diffraction. The results are shown in Table 2-3.   
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Table 2-3: Phases of calcium aluminate present in each mixture after heat treatments. An 
“X” indicates that phase is present. 
 
All room temperature samples contained a hydrated phase of CaAl2((OH)8(H2O)2) 
(H2O)1.84. In addition, room temperature Mixtures Aroom and Broom contained 
Ca3Al2(OH)12 and Mixture Croom  contained 3CaO·Al2O3·Ca(OH)2· 18H2O.   
All mixtures that were heat to 120 ºC contained the hydrated phase 
(CaO)3Al2O3(H2O)6.  Mixtures A650 and B650 contained a dehydrated phase, 
5(CaO)3Al2O3.  Finally all autoclaved samples contained the hydrated phase 
Ca3(Al(OH)6)2.  All mixtures at all heat treatments contained Al(OH)3 and its presence 
indicated that Al
3+
 had precipitated as Al(OH)3. Additionally, no aluminum metal was 
present. 
Figure 2-3shows a PXRD simulated pattern for Mixture Aauto and reference 
pattern matches for phases present. CaCO3, as mentioned above, was one of the two 
chemicals (the other being Al2O3) the CA aggregates were sintered from and it can 
sometimes been seen in the PXRD patterns as demonstrated in Figure 2-3. 
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Figure 2-3: PXRD simulated pattern for Mixture A autoclaved and reference pattern 
matches for phases present. A. Sample scan. B. Ca3(Al(OH)6)2 C. Al(OH)3 D. CaAl4O7 E. 
CaCO3 F. CaAl2O4. 
 
2.3.5 Biodegradability 
Figure 2-4 shows the average change in mass of the 10 disks of Mixtures A, B, 
and C versus time. The three disk types experienced similar cycles of a loss in mass 
followed by a gain in mass.  After the 26 weeks period, there was no significant overall 
loss or gain in mass occurring in the disks of any of the mixtures. 
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Figure 2-4: Average change in mass of Mixtures A, B, and C over 26 weeks. 
 
2.3.6 Fibroblast Attachment 
To determine which CA mixture would be optimal for biomaterial applications, 
disks of Mixtures A-C were cultured with NIH 3T3 fibroblasts. Three autoclaved 
substrates of each mixture (for each time period) were placed in a 48-well plate and 1mL 
of cells was added to each well.  After 1, 4, and 7 days, the number of live cells was 
determined using the Live/Dead/Viability/Cytotoxicity Assay Kit from Invitrogen. 
Samples were viewed using a Zeiss Axioskop 2 under 10x magnification and five images 
per sample with an area of 0.6 mm
2
 were taken using the Zeiss Axiocam. The number of 
live and dead cells per view was counted using the Axiovision 4 Software.  Three 
separate trials were completed following the same procedure.  The data was then 
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analyzed using one-way ANOVA with a Bonferroni post hoc test (p<0.05) to determine if 
there were any statistical differences in the number of live cells on the different mixtures. 
 
Figure 2-5: Day 1 Fibroblast attachment statistics. (Data labels=Mixture, average ± 
standard error)  One-way ANOVA with Bonferroni post hoc test, of average live cells per 
view p<0.05, * = different from all other samples. 
 
On Day 1 the average number of live cells per view (+/- standard deviation) was: 
Mixture A: 6.4 ± 6.0; Mixture B: 5.3 ± 6.3; and Mixture C: 6.8 ± 8.2 (Figure 2-5).  
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Figure 2-6: Day 4 Fibroblast attachment statistics. (Data labels=Mixture, average ± 
standard error)  One-way ANOVA with Bonferroni post hoc test, of average live cells per 
view p<0.05, * = different from all other samples. 
 
 On Day 4 the average number of live cells per view (+/- standard deviation) was: 
Mixture A: 13.9 ± 20.0; Mixture B: 6.4 ± 7.7; and Mixture C: 4.9 ± 6.6 (Figure 2-6). 
 
Figure 2-7: Day 7 Fibroblast attachment statistics. (Data labels=Mixture, average ± 
standard error)  One-way ANOVA with Bonferroni post hoc test, of average live cells per 
view p<0.05, * = different from all other samples. 
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  On Day 7 the average number of live cells per view (+/- standard deviation) was: 
Mixture A: 9.6 ± 10.7; Mixture B: 9.6 ± 7.2; and Mixture C: 6.8 ± 7.8 (Figure 2-7).  The 
statistical analysis showed that on Day 4, mixture A had significantly more live cells 
attached than Mixtures B and C.  
 
2.4 Discussion  
The average pore size of the CA material was easily controlled through the 
casting/hydration process. Five different mixtures were cast using different combinations 
of the four starting aggregates.  Each of the five mixtures was then subjected to one of 
four different heat treatments.  The mixtures had a range of average pore sizes from 
approximately 100 to 290 microns and it was found that heat treatment did not affect the 
average pore size of the material.  However, heat treatment did affect the strength of the 
material and the phases of calcium aluminate present in each mixture.   
 The strength of the CA is due to the hydrated phases which form during the 
casting process and interlock the different phases of the material.  This effect is seen after 
heat treating the cast CA to 650 ºC where the hydrated phases are no longer present and 
the strength of the material significantly decreases.  Autoclaving the CA significantly 
increased the strength of the mixtures.  This is due to the 18 psi of steam used in the 
autoclaving process.  The extra water from steam allows for increased dissolution of the 
material which then increases the precipitation of hydrated phases causing further 
interlocking of phases in turn increasing its strength.  The temperature of autoclaving did 
not affect the strength, as heating the samples to 120 ºC, the same temperature used in 
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autoclaving, in a dry environment with no steam or pressure did not have an effect on the 
strength of the material compared to CA with no heat treatment.  
The lack of significant gain or loss in mass of the CA during a 26 week period 
could be due to the hydration process of CA which involves initial dissolution of the CA, 
followed by nucleation and finally reprecipitation.
10
  This would also explain the cycling 
of losing and gaining mass. Some of the loss is due to the slight dissolution, and the small 
gains are due to the precipitation of the newly hydrated CA phases.   Also, the 
biodegradability was observed in a static environment in PBS.  Any concrete 
observations on biodegradability of CA would have to be done during in vivo testing due 
to the complex physiological environment surrounding implant materials. 
 
2.5 Conclusions 
After reviewing the results of the fibroblast adhesion, Mixture A with an average 
pore size of approximately 100µm was chosen for the remainder of the studies due to the 
increased cell adhesion on Day 4. This result is consistent with other studies that 
determined an average pore size of 100 to 150 microns was required for cell growth and 
proliferation on tricalcium phosphate, hydroxyapatite and calcium aluminate.
5, 11
  Mixture 
A was also chosen due to its increased strength over Mixtures B and C and autoclaving 
was also chosen as the sterilization method for studies as it increases the strength of the 
material. This mixture contains CaAl2O4, CaAl4O7, and Ca3(Al(OH)6)2 phases, is stable 
when autoclaved and in PBS for 6 months.  
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Chapter 3 : Increased Osteoblast Adhesion with 
Immobilization of KRSR on the Calcium Aluminate 
Surface 
3.1 Introduction 
Synthetic bone scaffolds can lead to the formation of fibrous tissue around the 
implant which inhibits productive cell adhesion and proliferation.  This is caused by non-
specific cell and protein adhesion in addition to the normal wound-healing response. 
These complications lead to bone resorption at the bone/implant interface causing 
implant loosening and ultimately implant failure.
1-4
 One way to increase cell adhesion is 
to combine cell adhesion peptides with scaffolds.  RGD (arg-gly-asp) is the well-known 
sequence domain that is present in many extracellular matrix proteins, including 
fibronectin, whose main function is to mediate the adhesion of cells.
5, 6
  Studies have 
shown that this peptide can increase the attachment of mesenchymal stem cells to 
different substrates (hydroxyapatite, titanium, polymer scaffolds) but does not enhance 
the spreading of the cells.
5-7
 Cell spreading is important for cell survival and cell 
differentiation into osteoblasts which are necessary for bone formation and regeneration.
5, 
6
  RGD is also a non-cell specific adhesion peptide meaning it increases the adhesion of 
many different types of cells which can also lead to unwanted fibrous tissue formation in 
a bone scaffold.   
Therefore, a peptide that binds transmembrane proteoglycans could improve cell 
attachment and spreading.
2
  For this application a peptide that could preferentially bind 
osteoblasts over other types of cells would be optimal.  An example of this type of 
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peptide is the KRSR (lys-arg-ser-arg) peptide.  KRSR-modified surfaces have been 
shown to bind increased numbers of osteoblasts compared to unmodified titanium 
surfaces and surfaces modified with RGD after four hours of incubation with cells.
2, 8, 9
 
Additionally, Hasenbein et al found that KRSR preferentially bound osteoblasts 
compared to fibroblasts on micropatterned surfaces of N1[3-(trimethoxysilyl)-propyl] 
diethylenetriamine/ octadecyltrichlorosilane.
9
   Fibrous tissue formation is a common 
cause of implant failure and because KRSR has been shown to preferentially bind 
osteoblasts over fibroblasts, KRSR may be more beneficial than RGD in bone 
applications.   
In this study, KRSR was covalently attached to the surface of cast calcium 
aluminate to potentially increase osteoblast adhesion on the surface and RGD was 
covalently attached to the surface as a control peptide for comparison purposes.  
Attachment was achieved through a multi-step deposition method. Each step of the 
attachment was characterized by Diffuse Reflectance Infrared Fourier Transform 
Spectroscopy (DRIFT). Fibroblast and osteoblast attachment on modified and unmodified 
substrates at Days 1, 4, and 7 was then determined using a 
Live/Dead/Viability/Cytotoxicity assay. 
 
3.2 Materials and Methods 
3.2.1 Materials 
Calcium aluminate aggregates were supplied by Westmoreland Advanced 
Materials.  KRSRC was purchased from Genscript (96.4% purity) as lyophilized powder 
and reconstituted in doubly distilled H2O (ddH2O).  RGDC was purchased from 
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American Peptide (99.3% purity)as lyophilized powder and was reconstituted in ddH2O.  
Tetrahydrofuran (THF, 99.9% purity) and acetonitrile (ACN, 99.9% purity) were 
purchased from ThermoFisher.  THF was distilled over sodium and benzophenone before 
use.  12-aminododecanoic acid (95%) was purchased from Sigma-Aldrich.  3-
maleimidopropionic acid N-hydroxysuccinimide (NHS) ester (99%), 2% osmium 
tetroxide, and hexamethyldisilazane (HMDS) were purchased from Alfa Aesar.  NIH 3T3 
Fibroblasts (CCL-92) were purchased from ATCC.  Dulbecco’s Modified Eagle Media 
(DMEM/High glucose, Hyclone), phosphate buffered saline (PBS, - calcium and 
magnesium, Hyclone) fetal bovine serum and penicillin/strepavidin were purchased from 
Fisher.  Normal Human Osteoblasts (NHOsts, CC-2538), cell culture reagents, and OGM 
media were purchased from LONZA.  Unless otherwise noted all chemicals were used as 
received.   
 
3.2.2 Casting Calcium Aluminate 
Calcium aluminate disks were prepared by a room temperature (20 ºC) cast of 
different sized calcium aluminate aggregates with phases CaAl2O4 and CaAl4O7. The 
aggregates were separated by size during a sifting process in which the cement was 
passed through wire screens of different size meshes and “caught” on another mesh size.  
Three different aggregate sizes (-30 + 60 (25%), -60 (25%), and -325 (50%)) were mixed 
together to form the disks in the casting process. The aggregates were dry mixed at room 
temperature to ensure complete particle distribution.  After dry mixing, doubly-distilled 
H2O was mixed in and the cement paste was allowed to sit for 20 minutes at room 
temperature to thicken.  Upon thickening, the cement was poured into a mold of 8 mm 
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diameter disks and allowed to sit overnight.  The phases of the final calcium aluminate 
disks used in the following experiments after casting and sterilization by autoclaving 
were: CaAl2O4, CaAl4O7, and Ca3(Al(OH)6)2. 
 
3.2.3 Covalent Peptide Attachment 
KRSR and RGD peptides with additional cysteine residues at the terminus were 
attached to the CA surface using a multi-step solution deposition.   First, the substrates 
were placed in a 1mM 12-aminododecanoic acid in dry tetrahydrofuran (THF) solution at 
room temperature for one hour. The excess solvent was then removed by placement in a 
120 ºC oven for 24 hours.  The 12-aminododecanoic acid modified CA disks were then 
placed in a 1mM 3-maleimidopropionic acid NHS ester in acetonitrile solution for 
24 hours.  The solvent was removed by vacuum (0.1 Torr) for 24 hours.  The substrates 
were then dipped in a 1 mg/mL solution of KRSR(C) or RGD(C) in ddH2O at 4ºC for 
24 hours, and then dried under vacuum for 24 hours (Scheme 3-1). Samples were then 
sterilized by autoclaving at 121 ºC and 18 psi of steam for 60 minutes with fast exhaust 
prior to cell testing. 
 
Scheme 3-1:Schematic representation of the three-step covalent attachment of KRSR(C) 
peptide to the CA surface. 
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3.2.4 Diffuse Reflectance Infrared Fourier Transform Spectroscopy 
A Thermo Nicolet Nexus 470 FT-IR Spectrophotometer equipped with a diffuse 
reflectance attachment was used to obtain the spectra of the substrates after each 
deposition step. Spectra were collected with 256 scans and a resolution of 4 cm
-1
. 
 
3.2.5 Fibroblast Adhesion 
NIH Swiss Albino mouse 3T3 fibroblasts were cultured until confluent and 
diluted to a concentration of 10,000 cells per milliliter of media (DMEM/High Glucose, 
10% FBS, 1% strepavidin/penicillin).  Three of each type of substrate (KRSR modified, 
RGD modified and unmodified CA (control)) per time point were placed in a 48-well 
plate and 1mL of cells was added to each well.  After 1, 4, and 7 days, the number of live 
cells was determined using the Live/Dead/Viability/Cytotoxicity Assay Kit from 
Invitrogen by counting the number of live (green) versus dead (red) cells.  Five spots on 
each sample with an area of 0.6 mm
2
 were imaged under 10 x magnification using the 
Axioskop2.  Three separate trials were completed with a total of 9 samples of each type 
with a total of 45 views for each sample type for each time point (control, RGD, KRSR).  
The data was then normalized to the average number of live osteoblasts on the 
unmodified CA at each time point and statistical analysis was done using Origin 8.0 
using a one-way ANOVA with a Bonferroni post hoc test (p<0.05).   
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3.2.6 Osteoblast Adhesion 
Normal human osteoblasts isolated from a 6 year old female were purchased from 
LONZA (NHOsts),  cultured until confluent and diluted to a concentration of 10,000 cells 
per one milliliter of media (OGM media, LONZA).  Three of each type of substrate per 
time point was placed in a 48-well plate and 1mL of cells was added to each well.  After 
1, 4, and 7 days, the number of live and total cells was determined following the 
procedure outlined in section 3.2.6.  
 
3.2.7 Cell Proliferation 
Normal human osteoblasts isolated from a 6 year old female were purchased from 
LONZA (NHOsts), cultured until confluent and diluted to a concentration of 10,000 cells 
per milliliter of media (OGM media, LONZA).  Briefly, a standard curve was made by 
plating 0 to 10,000 cells, that had been frozen at -70 °C, in 200 µL volumes of the 
CyQuant cell lysis/reagent buffer (Invitrogen) in a 96-well plate and the fluorescence was 
read on a microplate reader with excitation/emission at 480/520 nm. Then three KRSR 
modified CA and three unmodified CA per time point were placed in a 48-well plate and 
1mL of cells were added to each well.  After 1, 4, 7, and 14 days, the number of cells was 
determined using the CyQuant Cell Proliferation Assay Kit from Invitrogen.   
 At each time point, the CA samples were removed and placed into 1mL 0.025 % 
trypsin in a 1.5mL microcentrifuge tube in the incubator for 30 minutes at 37 ºC and 5 % 
CO2to detach the cells adhered to the samples. The samples were removed and the trypsin 
was centrifuged for 5 minutes at 2.2 x g.  The supernatant was removed and the cell pellet 
was frozen overnight at -70 ºC.  The cell pellets were then resuspended in 200 µL of the 
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cell lysis/reagent buffer and placed in a 96-well plate and the fluorescence was measured.  
The fluorescence was then compared to the standard curve to determine the number of 
cells present on the samples. 
 
3.2.8 Scanning Electron Microscopy 
Normal human osteoblasts isolated from a 6 year old female were purchased from 
LONZA (NHOsts), cultured until confluent and diluted to a concentration of 10,000 cells 
per milliliter of media (OGM media, LONZA).   KRSR modified CA and control CA 
were placed in a 48-well plate and 1mL of cells was added to each sample.  After 4 days, 
the media was removed from the samples, and they were fixed in 2 % glutaraldehyde (in 
PBS) for 5 days at 4 ºC. Samples were removed and washed twice with PBS and then 
immersed in 0.5 mL of 2 % Osmium tetroxide (OsO4) for 1 hour at room temperature.  
The OsO4 was removed and samples were washed 3 times with PBS and dehydrated in an 
ethanol series, by immersion for 20 minutes in each of 25, 50, 75, 90, and 100% ethanol.  
Samples were placed into new tubes and immersed in 1mL of HMDS for 10 minutes.  
Samples were placed in glass tubes and put into a dessicator for 1.5 hours before 
imaging.  Samples were imaged on a Hitachi S-3400N-II Variable Pressure SEM under 
vacuum. 
 
3.3 Results 
3.3.1 Covalent Peptide Attachment 
To increase osteoblast cell adhesion and therefore the biocompatibility of the CA 
surface, the cell adhesion peptides RGD and KRSR with terminal cysteine residues were 
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covalently attached to the CA surface. Covalently linking the peptide to the surface 
improves the adhesion strength of the peptide to the surface compared to physisorption of 
the peptide and it controls peptide orientation when it is placed into a physiological 
environment. Cysteine residues were added to the peptide sequence to facilitate 
immobilization. To immobilize the peptides on the CA surface, samples were immersed 
in a 1mM solution of 12-aminododecanoic acid (THF) for one hour at room temperature.  
Samples were removed from solution and placed in a 120 °C oven overnight.  The 
samples were then analyzed using Diffuse Reflectance Infrared Fourier Transform 
Spectroscopy (DRIFT) and the presence of the CH2 asymmetric and CH2 symmetric 
stretches at 2917 and 2848 cm
-1
, respectively, in the spectrum indicate that the 12-
aminododecanoic acid had been attached to the surface (Figure 3-1A). 
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Figure 3-1:DRIFT spectra for each step of peptide attachment. a) CH stretch region 
showing the CH2 symmetric and asymmetric stretches from the carbon chain of 12-
aminododecanoic acid to the CA surface.  b) The peak at 1711cm
-1 
from the C=O 
stretches of the imide ring of 3-maleimidopropionic acid. c) The peak at 669 cm
-1
 due to 
the formation of the C-S bond from the Michael addition of the cysteine residue to the 
imide ring. 
 
Next, the samples were placed in a 1mM solution of 3-maleimidopropionic acid 
N-hydroxysuccinimide ester for 24 hours at room temperature. The ester bond of the 3-
maleimidopropionic acid NHS ester was broken and an amide bond was formed between 
the 12-aminododecanoic acid on the surface and the 3-maleimidopropionic acid.  The 
samples were removed from solution and placed on a vacuum line (0.1 Torr) to remove 
any excess solvent. DRIFT was used to once again analyze the samples. The peak in the 
spectrum at 1711 cm
-1
 was assigned to the carbonyl bond stretches present on the imide 
ring and indicate that it had been successfully attached to the 12-aminododecanoic acid 
(Figure 3-1B).  The final step of the attachment was to place the samples in a 1 mg/mL 
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solution of either peptide for 24 hours at 4 °C where the cysteine terminated peptide goes 
through a Michael addition to the imide ring.  The samples were removed from solution 
and placed on the vacuum line overnight. The appearance of a peak at 669 cm
-1
 from the 
C-S bond stretch from the cysteine residue of the peptide indicated that the Michael 
addition had occurred through the cysteine residue and the peptide had been attached to 
the surface (Figure 3-1C). 
 
3.3.2 Fibroblast Adhesion 
To determine if the cell adhesion peptides increase the number of cells attached to 
the CA surface, NIH 3T3 cells were cultured until confluent and diluted to a 
concentration of 10,000 cells per milliliter of media.  Three autoclaved substrates of each 
type (unmodified, KRSR modified and RGD modified) for each time period were placed 
in a 48-well plate and 1mL of cells was added to each well.  After 1, 4, and 7 days, the 
number of live cells was determined using the Live/Dead/Viability/Cytotoxicity Assay 
Kit from Invitrogen and counted using the Axiovision 4 Software (Figure 3-2). 
 
Figure 3-2:Representative live/dead images of fibroblasts attached to control unmodified 
CA, KRSR modified and RGD modified CA at Days 1, 4, and 7. 
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  Three separate trials were completed following the same procedure as above.  
The data was then normalized to the unmodified CA with osteoblast cell data and 
analyzed using one-way ANOVA with a Bonferroni post hoc test (p<0.05) to determine if 
there were any statistical differences in the number of cells present on the materials.   
 
Figure 3-3:Day 1 Fibroblast and osteoblast attachment statistics. (Data labels=Sample 
type/cell line: CF=control/fibroblasts, KF=KRSR modified CA/fibroblasts, RF= RGD 
modified CA/ fibroblasts, CO= control/osteoblasts, KO=KRSR modified CA/osteoblasts, 
RO=RGD modified CA/osteoblasts)  One-way ANOVA with Bonferroni post hoc test, 
p<0.05, * = different from CF, X= different from all other samples. Data represented as 
mean ± standard error. 
On Day 1 the average number of normalized live fibroblasts per view (+/- 
standard deviation) was: control CA: 31.6 ± 5.6; KRSR modified: 104.0 ± 60.9; and RGD 
modified: 97.1 ± 84.6 (Figure 3-3). 
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Figure 3-4:Day 4 Fibroblast and osteoblast attachment statistics. (Data labels=Sample 
type/cell line: CF=control/fibroblasts, KF=KRSR modified CA/fibroblasts, RF= RGD 
modified CA/ fibroblasts, CO= control/osteoblasts, KO=KRSR modified CA/osteoblasts, 
RO=RGD modified CA/osteoblasts)  One-way ANOVA with Bonferroni post hoc test, 
p<0.05, * = different from CF, X= different from all other samples. Data represented as 
mean ± standard error. 
 
On Day 4: control CA: 63.7 ± 42.7; KRSR modified: 122.2 ± 83.6; and RGD 
modified: 122.7 ± 104.8 (Figure 3-4).   
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Figure 3-5:Day 7 Fibroblast and osteoblast attachment statistics. (Data labels=Sample 
type/cell line: CF=control/fibroblasts, KF=KRSR modified CA/fibroblasts, RF= RGD 
modified CA/ fibroblasts, CO= control/osteoblasts, KO=KRSR modified CA/osteoblasts, 
RO=RGD modified CA/osteoblasts)  One-way ANOVA with Bonferroni post hoc test, 
p<0.05, ^ = different from CF, CO, and RO, $= different from CF and KO. Data 
represented as mean ± standard error. 
 
On Day 7: control CA: 75.1 ± 78.2; KRSR modified: 224.4± 149.7; RGD 
modified: 201.8 ± 157.4 (Figure 3-5).Statistical analysis showed that the average number 
of live fibroblasts present on the samples that had been modified with cell adhesion 
peptides at all time points was statistically significantly higher than that of the 
unmodified CA control. However, there was no statistical difference between the 
numbers of live cells on the two peptide modified substrates (Figure 3-3 to Figure 3-5). 
 
3.3.3 Live Osteoblast Adhesion 
To determine if KRSR increased the number of osteoblasts attached to the CA 
surface when compared to the control and RGD modified surface, Normal Human 
Osteoblasts (LONZA) were cultured until confluent and diluted to a concentration of 
10,000 cells per milliliter of media (OGM, LONZA).  Three autoclaved substrates of 
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each type (control, KRSR modified and RGD modified) for each time period were placed 
in a 48-well plate and 1mL of cells was added to each well.  After 1, 4, and 7 days, the 
number of live and total cells was determined using the Live/Dead/Viability/Cytotoxicity 
Assay Kit from Invitrogen. Samples were viewed using a Zeiss Axioskop 2 under 10x 
magnification and five images per sample were taken using the Zeiss Axiocam. The 
number of live and dead osteoblasts per view was counted using the Axiovision 4 
software (Figure 3-6). Three separate trials were completed following the same 
procedure.  
 
 
Figure 3-6:Representative live/dead images of osteoblasts attached to control unmodified 
CA, KRSR modified and RGD modified CA at Days 1, 4, and 7. 
 
 On Day 1 the average number of live osteoblast cells per view (+/- standard 
deviation) was: control CA: 100; KRSR modified: 144.9 ± 58.0; and RGD modified: 
117.1 ± 56.1 (Figure 3-3).  On Day 4: control CA: 100; KRSR modified: 169.1 ± 68.3; 
and RGD modified: 125.7 ± 55.0 (Figure 3-4).  On Day 7: control CA: 100; KRSR 
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modified: 197.3 ± 95.9; and RGD modified: 151.6 ± 100.6 (Figure 3-5).  The data was 
normalized to the average number of live osteoblasts on unmodified CA at each time 
point and then analyzed using one-way ANOVA with a Bonferroni post hoc test (p< 
0.05). Analysis showed that number of live osteoblasts on the KRSR peptide modified 
samples at Days 1, 4 and 7 was statistically significantly higher than that of the RGD 
modified and control samples (Figure 3-3 to Figure 3-5). 
 
3.3.4 Total Osteoblast Adhesion 
 
Figure 3-7:Day 1 Total osteoblast attachment statistics. (Data labels=Sample type/cell 
line: C= control/osteoblasts, K=KRSR modified CA/osteoblasts, R=RGD modified 
CA/osteoblasts)  One-way ANOVA with Bonferroni post hoc test, p<0.05, $= different 
from all other samples. Data represented as mean ± standard error. 
 
The total osteoblast cell data was normalized to the average number of total cells 
determined above on the unmodified CA at each time point. On Day 1 the average 
number of total osteoblast cells per view (+/- standard deviation) was: control CA: 100; 
KRSR modified: 121.9 ± 46.9; and RGD modified: 101.7 ± 46.7 (Figure 3-7).   
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Figure 3-8:Day 4 Total osteoblast attachment statistics. (Data labels=Sample type/cell 
line: C= control/osteoblasts, K=KRSR modified CA/osteoblasts, R=RGD modified 
CA/osteoblasts)  One-way ANOVA with Bonferroni post hoc test, p<0.05, $= different 
from all other samples. Data represented as mean ± standard error. 
 
On Day 4: control CA: 100; KRSR modified: 130.3 ± 50.7; and RGD modified: 
106.7 ± 45.5 (Figure 3-8).   
 
Figure 3-9:Day 7 Total osteoblast attachment statistics. (Data labels=Sample type/cell 
line: C= control/osteoblasts, K=KRSR modified CA/osteoblasts, R=RGD modified 
CA/osteoblasts)  One-way ANOVA with Bonferroni post hoc test, p<0.05, *= different 
from C. Data represented as mean ± standard error. 
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On Day 7: control CA: 100; KRSR modified: 142.8 ± 61.7; and RGD modified: 
124.7 ± 81.8 (Figure 3-9).  The data was analyzed using one-way ANOVA with a 
Bonferroni post hoc test (p< 0.05). Analysis showed that the total number of osteoblasts 
on the KRSR peptide modified samples at Days 1, 4 and 7 was statistically significantly 
higher than that of the control samples and at Days 1 and 4 than that of the RGD samples 
(Figure 3-7 to Figure 3-9). 
 
3.3.5 Cell Proliferation 
Normal human osteoblasts (LONZA (NHOsts)) were cultured until confluent and 
diluted to a concentration of 10,000 cells per one milliliter of media (OGM media, 
LONZA).  Briefly, a standard curve was made by plating 0 to 10,000 cells, that had been 
frozen at -70 °C, in 200 µL volumes of the CyQuant cell lysis/reagent buffer (Invitrogen) 
in a 96-well plate and the fluorescence was read on a microplate reader with 
excitation/emission at 480/520 nm. The, three of each type of substrate per time point 
was placed in a 48-well plate and 1mL of cells were added to each well.  After 1, 4, 7, 
and 14 days, the number of cells was determined using the CyQuant Cell Proliferation 
Assay Kit.  Figure 3-10 shows the standard curve for the cell proliferation assay. 
61 
 
 
Figure 3-10: Cell Proliferation Standard Curve. Plot of number of cells versus 
fluorescence intensity showing linear regression and equation. 
 
 
Figure 3-11: Cell proliferation curve. Plot of mean number of cells (± standard 
deviation) vs. Days. 
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Figure 3-11 shows a plot of the mean number of cells (± standard deviation) vs. 
days of both the control CA and the KRSR modified CA. The number of cells on both 
samples decreased after Day 1, up until Day 7.  From Day 7 to Day 14, a slight increase 
in the number of cells is observed.  At Days 4, 7, and 14, a higher number of cells 
appears on the KRSR modified CA than on the control CA. 
 
3.3.6 Scanning Electron Microscopy 
To determine if cell adhesion peptide KRSR increased cell spreading on the CA 
surface, NHOsts (LONZA) were cultured until confluent and diluted to a concentration of 
10,000 cells per milliliter of media (OGM media, LONZA).  KRSR modified CA and 
control unmodified CA were placed in a 48-well plate and 1 mL of cells was added to 
each well.  After 4 days, the media was removed from the samples, and were fixed to 
maintain cell morphology.  
 
 
 
 
 
63 
 
A.  B.  
C.  D.  
Figure 3-12: Scanning Electron Micrographs.  A and B show images of rounded cells on 
control unmodified CA.  C and D show images of spread cells on KRSR modified CA. 
 
 Samples were imaged on a Hitachi S-3400N-II Variable Pressure SEM under 
vacuum. All osteoblasts present on the unmodified CA were small and rounded (Figure 
3-12A and B), whereas the osteoblasts present on the KRSR modified CA were spread 
and elongated (C and D). 
 
3.4 Discussion 
In vitro testing with fibroblasts showed that the cell adhesion peptides did 
increase cell attachment to the CA surface when compared to the control.  This is in 
agreement with the current literature that has shown that these peptides increase cell 
attachment to a variety of surfaces.
2, 5-18
 These results showed that the peptides were still 
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active on the surface and improved the biocompatibility of the CA surface. However, 
there was no statistical difference in the number of fibroblasts attached to the KRSR and 
RGD modified surfaces.  
Previous studies have shown that initially osteoblasts preferentially adhere to 
KRSR over other cell types and compared to other cell adhesion peptides. Dee et al 
showed that borosilicate surfaces modified with KRSR bound more osteoblasts than 
those modified with RGD and bound more osteoblasts than other cell types when 
incubating the surfaces with either osteoblast, endothelial cells, or fibroblasts at the 4 
hour time point.
8
  However, studies longer than 24 hours showed that RGD bound more 
osteoblasts than KRSR.  Schuler et al observed that RGD modified titanium and control 
titanium surfaces bound more osteoblasts than KRSR modified titanium after seven 
days.
17
 Our results indicate that on Days 1, 4, and 7, KRSR modified CA binds a higher 
number of osteoblasts compared to the RGD modified and control samples. Therefore on 
the CA surface, the KRSR peptide interacts more favorably with osteoblasts than the 
RGD cell adhesion peptide 
 A statistical comparison (one-way ANOVA, Bonferroni post hoc test, p<0.05) 
was done between the fibroblast and osteoblast cell trials to determine if the KRSR 
peptide preferentially bound osteoblasts over fibroblasts.  On Days 1, 4, and 7, KRSR 
was shown to bind more osteoblasts than RGD and unmodified CA, and on Days 1 and 4 
more osteoblasts than fibroblasts.  On Day 7,there was no statistical difference between 
the number of fibroblasts or osteoblasts bound by the KRSR modified samples. It was 
also observed that the control CA samples bound more osteoblasts than fibroblasts on 
Day 1.  
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This was also evident in the cell proliferation assay. Both the unmodified and 
KRSR modified CA samples had a decrease in the number of cells from Day 1 to Day 7, 
and then a slight increase from Day 7 to Day 14.  The initial decrease is expected as the 
cells that were not adhered well are no longer present on the samples after Day 1 and the 
NHOsts are a primary cell line which proliferates rarely and at a much slower rate than 
the NIH 3T3 fibroblasts.  Also it is not known if all of the cells attached to the samples 
were removed by incubation in trypsin. 
Another method of evaluating material suitability for biological purposes is to 
study the morphology of the cells on the surface. Cell spreading is necessary for cell 
viability and proliferation.  If cells are rounded as opposed to spread on the surface, they 
are unable to survive and proliferate. One way to examine the morphology of cells on a 
surface is through Scanning Electron Microscopy (SEM). Control unmodified and KRSR 
modified CA were incubated with osteoblasts for 4 days to allow for complete adherence 
of the cells to the surface.  The samples were then fixed and analyzed using SEM. SEM 
images indicate that attaching the KRSR peptide to the calcium aluminate surface 
allowed for osteoblast spreading, whereas the osteoblasts present on the unmodified CA 
were rounded. 
 
3.5 Conclusions 
Porous calcium aluminate scaffolds were cast at room and two cell adhesion 
peptides, KRSR and RGD were covalently linked to the CA surface using a multi-step 
solution deposition method.    Both peptides increased the fibroblast adhesion compared 
to the control surface. KRSR increased osteoblast adhesion when compared to the control 
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and RGD modified surface.  KRSR also allowed spreading of osteoblasts on the CA 
surface, whereas unmodified CA did not. The CA scaffold modified with KRSR would 
offer a surface that attracts more osteoblasts than fibroblasts which is advantageous when 
trying to increase bone cell growth.   
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Chapter 4 : Antibacterial Activity of Vancomycin and 
Ampicillin Immobilized on the Calcium Aluminate Surface 
4.1 Introduction 
The risk of implant associated infections is significant even with the advancements 
in sterile techniques and facilities in operating rooms.  Infection can be as high as 4 % in 
primary and 30 % in revision arthroplasties alone.
1-9
 These bacterial infections can lead to 
painful revision surgeries and implant failure.  Current antibiotic therapies are not 
effective against these infections that often stem from resistant biofilms. The biofilms are 
mainly comprised of biofilm anchored bacteria, a polysaccharide extracellular matrix and 
some free- floating planktonic bacteria that could infect other areas of the body. The 
extracellular polysaccharide matrix protects the biofilm from any harsh environment or 
chemicals including antibiotics.
8-13
 This makes it almost impossible for oral or injected 
antibiotics to eradicate the entire infection and re-infection often occurs with the new 
implant. Biofilms also increase antibiotic resistance as the antibiotics are introduced to 
fight the infection are unable to penetrate into the biofilms protective extracellular 
polysaccharide matrix and are only able to kill some of the planktonic bacteria.
6, 10, 11, 14, 15
 
One of the most common bacteria found in implant associated infections is 
Staphylococcus aureus (S. aureus). 
One way to combat these infections would be to attach low doses of antibiotics to 
the surface of the implants. Attaching the antibiotics to the surface would allow them to 
be active locally and immediately after implantation of the device. This would inhibit 
initial bacteria growth and attachment to the implant. Two different methods of attaching 
antibiotics to the surface are adsorption or covalent linkage. Both of these attachment 
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methods to biomaterials would make the antibiotics available immediately after 
implantation reducing the risk of infection and would allow for the use of smaller dosages 
of antibiotics.  These smaller dosages and the use of a local delivery system (vs. systemic 
delivery) will reduce the risk of antibiotic resistance. 
In this study, ampicillin and vancomycin were either adsorbed or covalently 
attached to the calcium aluminate surface and evaluated for their biological activity 
against a Staphylococcus aureus strain of bacteria (UAMS1) and/or Escherichia coli. 
Adsorption of molecules to a surface is achieved through a physisorption of the molecule 
through interactions such as hydrogen bonding, van der Waals forces, and dipole 
interactions, between functional groups on the surface and on the molecule. These 
adsorption interactions are generally not as strong as covalent or ionic interactions.  
Antibiotics adsorbed to the surface could be more easily removed by shear forces of 
blood flow. Additionally, another biomolecule in the surrounding tissue may provide a 
more favorable interaction, thus removing the antibiotic from the implant. 
Covalently linking molecules to a surface allows them to be anchored to the 
surface for more control over their presentation to the biological environment.   If the site 
of attachment is chosen appropriately the molecule will remain bioactive. However, some 
attachment methods may lead to inactivity. Therefore, careful surface synthesis, 
characterization and activity analysis is required. Covalent attachment may also lead to 
longer retention times in physiological environments which would lead to longer 
effectiveness. 
Two common antibiotics prescribed for implant associated infections are 
ampicillin and vancomycin. Ampicillin is a common antibiotic used to fight infections in 
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a systemic manner and is one of the first lines of defense. It is a penicillin beta lactam 
type antibiotic that is effective against gram positive and some gram negative bacteria by 
inhibiting the third stage of cell wall synthesis by binding to and acylating the 
transpeptidases that catalyze the cross-linking of the peptidoglycan cell wall leaving the 
enzyme inactive.
15-17
 Vancomycin is a glycopeptide antibiotic that is effective against 
gram positive bacteria by inhibiting proper cell wall synthesis.  Vancomycin binds to the 
D-ala-D-ala termini of the growing peptidoglycan wall and prevents the transpeptidases 
from accessing the pentapeptide and ultimately prevents its crosslinking.
14, 15, 18-21
  
Vancomycin forms five hydrogen bonds with the peptidoglycan terminal residues 
through four hydrogens and one oxygen from five secondary amides (Scheme 4-1). Both 
ampicillin and vancomycin leave the bacteria cells unable to respond to changes in 
osmotic pressure with improperly linked cell walls and the cells lyse.  
 
Scheme 4-1: Schematic representation of the interaction between vancomycin and the D-
ala-D-ala residues on the bacterial wall peptidoglycan. 
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 The goal of this project was to adsorb and covalently attach ampicillin and 
vancomycin to the calcium aluminate surface to add antibacterial properties to the 
material.  Each step of the attachment was verified using Diffuse Reflectance Infrared 
Fourier Transform Spectroscopy (DRIFT).  Antibacterial effectiveness was determined 
by a bacterial turbidity test in liquid culture and a zone inhibition assay on Mueller-
Hinton 2 agar using Staphylococcus aureus (UAMS1) for both antibiotics and 
Escherichia coli for ampicillin. 
 
4.2 Materials and Methods 
4.2.1 Materials 
Calcium aluminate aggregates were supplied by Westmoreland Advanced 
Materials.  Tetrahydrofuran (THF, 99.9% purity), methanol (MeOH, Certified ACS, 
>99.8% pure), Molecular Biology Grade Water (Hyclone), and Difco Tryptic Soy Broth 
were purchased from Thermo Fisher.  THF was distilled over sodium and benzophenone 
before use.  Vancomycin hydrogen chloride from Streptomyces orientalis, ampicillin 
sodium salt, 1,12-dodecanedicarboxylic acid, N-hydroxysuccinimde, and Mueller-Hinton 
2 agar were purchased from Sigma-Aldrich.  N’N’-dicyclohexylcarbodiimide was 
purchased from Fluka. S. aureus strain UAMS1 was provided by Allegheny General 
Singer Center for Genomic Sciences. E.coli (DH5α) was provided by Dr. Michael Cascio 
at Duquesne University. Normal Human Osteoblasts (NHOsts, CC-2538), osteoblast 
culturing reagents, and OGM media were purchased from LONZA. All materials were 
used as received unless otherwise noted. 
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4.2.2 Casting Calcium Aluminate 
Calcium aluminate disks were prepared by a room temperature (20 ºC) cast of 
different sized calcium aluminate aggregates with phases CaAl2O4 and CaAl4O7. The 
aggregates are separated by size during a sifting process in which the cement is passed 
through wire screens of different size meshes and “caught” on another mesh size.  Three 
different aggregate sizes (-30 + 60 (25%), -60 (25%), and -325 (50%)) were mixed 
together to form the disks in the casting process. The aggregates were dry mixed at room 
temperature to ensure complete particle distribution.  After dry mixing, doubly-distilled 
H2O was mixed in and the cement paste was allowed to sit for 20 minutes at room 
temperature to thicken.  Upon thickening, the cement was poured into a mold of 8 mm 
diameter disks and allowed to sit overnight.  The phases of the final calcium aluminate 
disks used in the following experiments present in the disks after casting and sterilization 
by autoclaving are: CaAl2O4, CaAl4O7, and Ca3(Al(OH)6)2. 
 
4.2.3 Covalent Antibiotic Attachment 
Ampicillin and vancomycin were covalently attached to the calcium aluminate 
surface using a multi-step solution deposition.   First, the calcium aluminate disks were 
placed in a 1mM 1,12-dodecanedicarboxylic acid in dry tetrahydrofuran (THF) solution 
at room temperature for one hour.  The excess solvent was removed by placement in a 
120 ˚C oven for 24 hours.  The 1,12-dodecanedicarboxylic acid modified disks were 
placed in a solution that was 2mM N’N’-dicyclohexylcarbodiimide (DCC) and 2mM N-
hydroxysuccinimide (NHS)  in dry THF for 24 hours.  The solvent was removed by 
vacuum (0.1 Torr) for 24 hours.  The disks were then dipped in a 1 mg/mL solution of 
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either ampicillin or vancomycin in methanol (MeOH) at 30 ºC for 24 hours, and dried 
under vacuum for 24 hours. (Scheme 4-2) Samples were sterilized by autoclaving at 121 
ºC and 18 psi of steam for 60 min with fast exhaust prior to antibiotic testing. 
 
Scheme 4-2: Schematic representation of the three-step covalent attachment of 
vancomycin to the calcium aluminate  surface. 
 
4.2.4 Adsorption of Antibiotics 
Calcium aluminate disks were immersed in a 1 mg/mL solution of either 
ampicillin or vancomycin (MeOH) at room temperature for 24 hours followed by excess 
solvent removal by vacuum for 24 hours. Samples were sterilized by autoclaving as 
described above. 
 
4.2.5 Diffuse Reflectance Infrared Fourier Transform Spectroscopy 
A Thermo Nicolet Nexus 470 FT-IR Spectrophotometer equipped with a diffuse 
reflectance attachment was used to obtain the spectra of the substrates after each 
deposition step. Spectra were collected with 256 scans and a resolution of 4 cm
-1
. 
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4.2.6 Staphylococcus aureus Bacterial Turbidity Tests 
A standard optical density analysis of bacterial growth was used to determine the 
antibiotic activity of ampicillin and vancomycin attached on the calcium aluminate 
surface against gram positive bacteria S. aureus (UAMS1). The bacteria was diluted to 
0.1 optical density at 600 nm (OD600nm) in Tryptic soy broth with 0.1 M NaCl and 0.08 % 
glucose.  Two milliliters of the bacterial suspension was placed in with each type of 
sample. There were five samples of each type in each trial for three separate trials. 
Samples were incubated at 37 ºC and 5 % CO2 for 3.5 hours.  The disks were then 
removed from the bacterial solution and the optical density at 600 nm was recorded. 
Statistical analysis of the average optical density at 600 nm was done using a one-way 
ANOVA with a Bonferroni post hoc test (Origin 8.0) (p<0.05).  The sample groups were: 
no disk (B, bacteria only), control unmodified calcium aluminate disk (C), ampicillin 
adsorbed to the disk (A), ampicillin linked to the disk (AL), vancomycin adsorbed to disk 
(V), and vancomycin linked to the disk (VL). A set of control vancomycin 30µg disks 
(VS) was also tested to compare to the vancomycin modified samples. 
 
4.2.7 Staphylococcus aureus Zone Inhibition Assay 
A standard zone inhibition assay was used to determine the activity of the 
antibiotics attached to the calcium aluminate surface compared to the standard antibiotic. 
S. aureus (UAMS1) was diluted to 0.1 OD600nm in Tryptic soy broth with 0.1 M NaCl and 
0.08 % glucose and spread onto Mueller-Hinton 2 Agar plates with cotton swabs.  Five 
plates for each antibiotic were used for each trial with a total of three trials.  The plate set 
up for the vancomycin assay was: a standard disk of 30 µg of vancomycin (VS) was 
77 
 
placed in the upper left quadrant of the plate, C-upper right, V-lower left, and VL-lower 
right. The plate set up for the ampicillin assay was: a standard disk of 10 µg of ampicillin 
(AS) was placed in the upper left quadrant of the plate, C-upper right, A-lower left, and 
AL-lower right. Plates were incubated agar side down (to ensure samples did not 
displace) for 24 hours at 37 ºC and 5 % CO2.  The diameter of the zone with the absence 
of bacterial growth was then measured in millimeters. Statistical analysis using a one-
way ANOVA with Bonferroni post hoc test (p<0.05) was used to determine any 
differences in the diameters of the zones produced. 
 
4.2.8 Escherichia coli Bacterial Turbidity Tests 
A standard optical density analysis of bacterial growth was used to determine the 
antibiotic activity of ampicillin attached to the calcium aluminate surface against gram 
negative bacteria. E.coli (DH5α) was diluted to 0.1 optical density at 600 nm (OD600nm) 
in Lysogeny Broth.  Two milliliters of the bacterial suspension was placed in with each 
type of sample. There were five samples of each type in each trial for three separate trials. 
Samples were incubated at 37 ºC and 5 % CO2 for 3.5 hours.  The disks were then 
removed from the bacterial solution and the optical density at 600 nm was recorded. 
Statistical analysis of the average optical density at 600 nm was done using Origin 8.0 
using a one-way ANOVA with a Bonferroni post hoc test (p<0.05).  The sample groups 
were: no disk (B, bacteria only), control unmodified calcium aluminate disk (C), 
ampicillin adsorbed to the disk (A), and ampicillin linked to the disk (AL).  
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4.2.9 Escherichia coli Zone Inhibition Assay 
A standard zone inhibition assay was used to determine the activity of the 
antibiotics attached to the calcium aluminate surface compared to the standard antibiotic. 
E.coli (DH5α) was diluted to 0.1 OD600nm in Lysogeny Broth and spread onto Mueller-
Hinton 2 Agar plates with cotton swabs.  Five plates for each antibiotic were used for 
each trial with a total of three trials.  The plate set up for the ampicillin assay was: a 
standard disk of 10 µg of vancomycin (AS) was placed in the upper left quadrant of the 
plate, C-upper right, A-lower left, and AL-lower right. Plates were incubated agar side 
down (to ensure samples did not displace) for 24 hours at 37 ºC and 5 % CO2.  The 
diameter of the zone with the absence of bacterial growth was then measured in 
millimeters.  
 
4.2.10 Release of Vancomycin 
To determine the difference in drug release between the vancomycin adsorbed 
and linked samples, calcium aluminate with adsorbed vancomycin and with linked 
vancomycin was soaked in Molecular Biology Grade water for 1, 3.5, and 24 hours. At 
each time point, the disks were removed and the water was analyzed using Electrospray 
Ionization Time of Flight Mass Spectroscopy on a Bruker microTOF.  Samples were 
analyzed in positive mode.  The following settings were used: endplate set off = - 500 V; 
capillary voltage = -4500 V; nebulizer = 0.4 Bar; nitrogen dry gas = 4.0 l/min; dry 
temperature = 200 ºC; capillary exit voltage = 139.0 V; skimmer 1 = 40.0 V; Hexapole 1 
= 23.0 V; Hexapole RF = 500.0 V; and skimmer 2 = 22.0 V. 
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4.2.11 Osteoblast Adhesion to Antibiotic Modified Calcium Aluminate 
Normal human osteoblasts isolated from a 6 and 11 year old female, respectively, 
and purchased from LONZA (NHOsts) were cultured until confluent and diluted to a 
concentration of 10,000 cells per one milliliter of media (OGM media, LONZA).  Three 
of each type of substrate per time point were placed in a 48-well plate and 1mL of cells 
was added to each well.  After 1, 4, and 7 days, the number of cells were determined 
using the Live/Dead/Viability/Cytotoxicity Assay Kit from Invitrogen by counting the 
number of live (green) versus dead (red) cells.  Five spots on each sample with an area of 
0.6 mm
2
 were imaged under 10x magnification using the Axioskop2.  Three separate 
trials were completed with a total of 9 samples of each type with a total of 45 views for 
each sample type for each time point. The data was then normalized to the average 
number of live or total osteoblasts on the  unmodified CA at each time point and 
statistical analysis was done using Origin 8.0 using a one-way ANOVA with a 
Bonferroni post hoc test (p<0.05).   
 
4.3 Results 
4.3.1 Covalent Antibiotic Attachment 
To add antibacterial activity to the calcium aluminate material, ampicillin and 
vancomycin were attached to the surface, separately.  Covalently linking the antibiotic to 
the surface controls antibiotic orientation at the surface of the implant material and its 
stability on the surface. This would allow for a strictly local dose aimed at reducing 
implant infection by bacterial attachment and subsequent biofilm formation.  To 
immobilize the antibiotic on the surface, samples were immersed in a 1mM solution of 
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1,12-dodecanedicarboxylic acid (THF) for one hour at room temperature.  Samples were 
removed from solution and placed in a 120 °C oven overnight.  The samples were then 
analyzed using Diffuse Reflectance Infrared Fourier Transform Spectroscopy (DRIFT) 
and the presence of the CH2 asymmetric and CH2 symmetric stretches at 2916 and 2848 
cm
-1
, respectively, in the spectrum indicated that the 1,12-dodecanedicarboxylic acid had 
been attached to the surface (Figure 4-1A).
22, 23
  The COOH region of the infrared 
spectrum contained several peaks that were due to both the binding of the dicarboxylic 
acid molecule to the surface through one of the carboxylic acid end groups and the 
presentation of the other carboxylic acid tail group at the interface for use in further 
reactions (Figure 4-1B). The peaks at 1707 cm
-1
 (C=O stretching) and 1377 cm
-1
 (C-O-H 
stretching) were due to the tail carboxylic acid group which can be used in further 
reactions. The large peak at 1566 cm
-1
was consistent with bidentate bonding of the acid 
to the surface in a carboxylate-like motif.
24
 Next, the samples were placed in a 2mM 
N’N’-dicyclohexylcarbodiimide (DCC)/ 2mM N-hydroxysuccinimide (NHS) solution in 
dry THF for 24 hours at room temperature. The samples were removed from solution and 
placed on a vacuum line (0.1 Torr) to remove any excess solvent. The DCC reacted first 
with the COOH tail group and then was displaced by the NHS.  DRIFT was used to once 
again analyze the samples and the peak in the spectrum at 1701 cm
-1
 was assigned to the 
stretching of the carbonyl bond on the succinimide ring. This indicated that the 
succinimide ring had been successfully attached to the carbon chain (Figure 4-1C).  The 
final step of the attachment was to place the samples in a 1 mg/mL solution of the 
antibiotic for 24 hours at 4 °C. The NHS was displaced and an amine group on the 
antibiotic reacted with O
-
forming an amide bond.  The samples were removed from 
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solution and placed on the vacuum line overnight. Vancomycin immobilization was 
confirmed by the appearance of a peak at 1235 cm
-1
 which is attributed to the amine 
groups present in the vancomycin structure (Figure 4-1D).  Ampicillin immobilization 
was confirmed by the appearance of peaks in the spectrum from 1792 to 1733 cm
-1
 due to 
different carbonyl groups present in the ampicillin structure (Figure 4-1E). 
 
Figure 4-1: DRIFT spectra characterizing the attachment of the antibiotic to the surface. 
A) CH2 asymmetric and symmetric stretches at 2916 and 2848 cm
-1
 due to the alkyl chain 
in 1,12-dodecanedicarboxylic acid. B) Peak at 1701 and 1377 cm
-1
 due to the “free” 
carboxylic groups from the C=O and C-O-H stretching respectively.  Peak at 1566 cm
-
1
consistent with the bidentate bonding of the acid to the surface. C) Peak at 1701 cm
-1
 
assigned to the carbonyl bond stretches present on the succinimide ring. D) Peak at 1235 
cm
-1
 in the vancomycin attachment from amine groups present in the vancomycin 
structure. E) Peaks between 1792 and 1733 cm
-1 
in the ampicillin attachment from the 
carbonyl groups present in the ampicillin structure. 
 
4.3.2 Adsorption of Antibiotics 
Covalent linkage of biomolecules to a surface could render them inactive; for this 
reason a second attachment method was investigated. Ampicillin or vancomycin was 
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adsorbed by immersing the disks in a 1 mg/mL solution of the antibiotic in methanol for 
24 hours at room temperature. The samples were then placed on a vacuum line and 
excess solvent and antibiotic were removed for 24 hours at 0.1 Torr. DRIFT was used to 
determine the presence of the antibiotic on the surface after adsorption.  Figure 4-2A, is 
the DRIFT of solid vancomycin powder. The peaks present at 2960, 2935, and 2876 cm
-1
 
are due to CH3 and secondary amide groups, respectively. Figure 4-2B shows the 
vancomycin adsorbed to the surface. The peaks present at 2954, 2932, and 2871 cm
-1
, 
were consistent with those in the vancomycin solid.  
 
Figure 4-2:Adsorption of vancomycin to the surface.  A) DRIFT of solid vancomycin 
powder. Peaks at 2960, 2935, and 2876 cm
-1 
are due to the CH3 groups and secondary 
amides respectively. B) Vancomycin adsorbed to the surface. The peaks present at 2954, 
2932, and 2871 cm
-1
 are consistent with those seen in the solid vancomycin powder. 
 
Figure 4-3A shows the DRIFT of solid ampicillin powder.  The peaks present at 
2980, 2923, and 2873 cm
-1
 are due to the CH3, CH2, and secondary amide groups, 
respectively. Figure 4-3B shows the ampicillin adsorbed to the calcium aluminate 
surface. The peaks at 2977, 2923, and 2862 were consistent with that of solid ampicillin.  
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Figure 4-3: Adsorption of ampicillin to the surface.  A) DRIFT of solid ampicillin 
powder. Peaks at 2980, 2923, and 2873 cm
-1 
are due to the CH3, CH2groups and 
secondary amides respectively. B) Ampicillin adsorbed to the surface. The peaks present 
at 2977, 2923, and 2863 cm
-1
 are consistent with those seen in the solid ampicillin 
powder. 
 
4.3.3 Staphylococcus aureus Bacterial Turbidity Test 
Antibiotic activity in culture was determined by a standard optical density test for 
bacteria. S. aureus (UAMS1) was diluted to an optical density of 0.1 (at 600 nm).  Two 
milliliters of the bacterial solution was placed in a 15 mL centrifuge tube with each of the 
samples.  Five samples each of the bacteria solution with no disk (B), control unmodified 
calcium aluminate disks (C), adsorbed ampicillin (A), linked ampicillin (AL), adsorbed 
vancomycin (V), linked vancomycin (VL), and a 30µg vancomycin standard (VS) were 
used in each trial.  Samples were incubated for 3.5 hours at 37 ºC with 5% CO2.  The 
samples were then removed from the incubator and the optical density at 600 nm was 
recorded.  A one-way ANOVA (p < 0.05) with Bonferroni post hoc test (p < 0.05, or 
0.01, or 0.001) was used to determine the statistical significance in bacterial growth 
inhibition (Figure 4-4). The OD600nmfor the samples were: B= 0.564 ± 0.137; C= 0.406 ± 
0.145; A= 0.412 ± 0.183; AL= 0.401 ± 0.197; V= 0.186 ± 0.062; VL= 0.185 ± 
0.067;VS= 0.269 ± 0.006.   
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Figure 4-4:One-way ANOVA with Bonferroni post hoc test of bacterial turbidity test 
data. Data is represented as the mean OD600nm ± standard error. B=bacterial solution no 
sample, C=unmodified CA, A=adsorbed ampicillin/CA, AL=ampicillin linked/CA, 
V=adsorbed vancomycin/CA, and VL=vancomycin linked/CA.  (X, p<0.05 with respect 
to B; #, p<0.001 with respect to B, C, and A, and p<0.01 with respect to AL; *, p<0.001 
with respect to all samples except V). 
 
Unmodified disks (C) and ampicillin linked disks (AL) significantly inhibited 
bacterial growth compared to the bacterial solution (B) with no sample (p < 0.05).  
Vancomycin adsorbed disks (V) inhibited bacterial growth significantly compared to the 
bacteria solution, adsorbed ampicillin disks (A), ampicillin linked disks (AL), and the 
unmodified disks. Vancomycin linked disks (VL) inhibited bacterial growth significantly 
compared to all samples except V (p < 0.001).  There was no statistical significance 
found between vancomycin adsorbed or linked to the disks in their ability to inhibit 
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bacterial growth in culture (Figure 4-4).  Both V and VL were significantly better at 
inhibiting bacteria growth when compared to VS, indicating that our surfaces are just as, 
if not more effective at inhibiting bacteria growth than a dosage of 30 µg of vancomycin 
(VS) ( p< 0.05) (Figure 4-5). 
 
Figure 4-5:One-way ANOVA with Bonferroni post hoc test of vancomycin data. Data is 
represented as the mean OD600nm ± standard error. V = adsorbed vancomycin, VL = 
vancomycin linked, VS = 30µg vancomycin standard. (^, p < 0.05 with respect to VS). 
 
4.3.4 Staphylococcus aureus Zone Inhibition Assays 
To determine the effectiveness of the antibiotics on the disk surface when 
compared to a control dosage (30 µg of vancomycin, or 10 µg of ampicillin) of the 
antibiotic, a zone inhibition assay was used.  S. aureus (UAMS1) was diluted to 0.1 
OD600nm in Tryptic soy broth with 0.1 M NaCl and 0.08 % glucose and spread onto 
Mueller-Hinton 2 Agar plates with cotton swabs. For the vancomycin assay, one sample 
each of the standard antibiotic 30 μg of vancomycin (VS), C, V, and VL was placed on 
each plate. For the ampicillin assay, one sample each of the standard antibiotic 10 µg of 
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ampicillin (AS), C, A, and AL was placed on each plate. Five plates for each antibiotic 
were used for each trial with a total of three trials.  Plates were then incubated agar side 
down (to ensure no displacement of the disks) for 24 hours at 37 ºC and 5 % CO2.  After 
24 hours the zone of inhibition around the disk was measured.   
 
A.  B.  
Figure 4-6:Photographs of sample zone inhibition assay plates. A) Sample plate of 
vancomycin zone inhibition assay. Top left: standard 30μg vancomycin disk; top right: 
unmodified CA disk; bottom left: vancomycin adsorbed on CA; bottom right: 
vancomycin linked to CA. B) Sample plate of ampicillin inhibition assay. Top left: 
standard 10μg ampicillin disk; top right: unmodified CA disk; bottom left: ampicillin 
adsorbed on CA; bottom right: ampicillin linked to CA. 
 
A one-way ANOVA with a Bonferroni post hoc test (p<0.05) was used to 
determine the statistical difference in the zones of inhibition of bacterial growth. For 
vancomycin, the average zones were: 30 μg vancomycin (VS) = 17± 1 mm; unmodified 
(C) = 0 mm; adsorbed vancomycin (V) = 16 ± 6 mm; linked vancomycin (VL) = 14 ± 2 
mm (Figure 4-6A).  For ampicillin, only the control 10 µg disk of ampicillin produced a 
zone of 19 ± 2 mm (Figure 4-6B). There was no statistical difference between the sizes of 
the zones of inhibition of the vancomycin modified CA and the control dosage (Figure 
4-7). 
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Figure 4-7: One-way ANOVA with Bonferroni post hoc test of vancomycin data. Data is 
represented as the mean zone(mm) ± standard error. V = adsorbed vancomycin, VL = 
vancomycin linked, VS = 30µg vancomycin standard. (p<0.05) 
 
4.3.5 Escherichia coli Bacterial Turbidity Test 
Antibiotic activity of ampicillin against gram-negative bacteria in culture was 
determined by a standard optical density test for bacteria. E.coli (DH5α) was diluted to an 
optical density of 0.1 (at 600 nm).  Two milliliters of the bacterial solution was placed in 
a 15mL centrifuge tube with each of the samples.  Five samples each of the bacteria 
solution with no disk (B), control unmodified calcium aluminate disks (C), adsorbed 
ampicillin (A), and linked ampicillin (AL) were used in each trial with a total of 3 trials.  
Samples were incubated for 3.5 hours at 37 ºC with 5 % CO2.  The samples were then 
removed from the incubator and the optical density at 600 nm was recorded.  A one-way 
ANOVA (p < 0.05) with Bonferroni post hoc test was used to determine the statistical 
significance in bacterial growth inhibition.  The OD600nmfor the samples were: B= 1.22 ± 
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0.25; C= 1.29 ± 0.23; A= 1.22 ± 0.15; and AL= 1.26 ± 0.24.  (Figure 4-8) No statistical 
difference was observed between sample types. 
 
Figure 4-8: One-way ANOVA with Bonferroni post hoc test of E.coli bacterial turbidity 
test data. Data is represented as the mean OD600nm ± standard error. B=bacterial 
solution no sample, C=unmodified CA, A=adsorbed ampicillin/CA, AL=ampicillin 
linked/CA. (p<0.05) 
 
4.3.6 Escherichia coli Zone Inhibition Assays 
To determine the effectiveness of the ampicillin on the disk surface when compared 
to a control dosage (10µg of ampicillin) of the antibiotic, a zone inhibition assay was 
used. E.coli (DH5α) was diluted to 0.1 OD600nm in Lysogeny Broth and spread onto 
Mueller-Hinton 2 Agar plates with cotton swabs. For the assay, one sample each of the 
standard antibiotic 10µg of ampicillin (AS), C, A, and AL was placed on each plate. Five 
plates for each antibiotic were used for each trial with a total of three trials.  Plates were 
then incubated agar side down (to ensure no displacement of the disks) for 24 hours at 37 
ºC and 5 % CO2.  After 24 hours the zone of inhibition around the disk was measured.  
Only the control 10µg disk of ampicillin produced a zone of 25 ± 4 mm. 
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4.3.7 Release of Vancomycin 
To determine the difference in drug release between the vancomycin modified 
samples, calcium aluminate with adsorbed vancomycin and with linked vancomycin were 
soaked in Molecular Biology Grade Water for 1, 3.5, and 24 hours. At each time point, 
the disks were removed and the water was analyzed using Electrospray Ionization Time 
of Flight Mass Spectroscopy on a Bruker microTOF.  For all samples a peak at 471.3 m/z 
was observed.  This corresponds to the vancomycin molecule with the loss of one 
chlorine atom, with a total charge of + 3.  For the calcium aluminate samples with 
adsorbed vancomycin, the counts for the peak observed at 471.3 were after 1 hour 5806 
counts (Figure 4-9A), after 3.5 hours 421 counts (Figure 4-9B), and after 24 hours 12,090 
counts (Figure 4-9C). 
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A.  
B.  
C.  
Figure 4-9: Release of adsorbed vancomycin. A) Mass spectra after 1 hour soak in 
molecular biology grade water.   B) Mass spectra after 3.5 hour soak C) Mass spectra 
after 24 hour soak.  Peak at 471.3 corresponds to vancomycin with the loss of a chlorine 
and an overall charge to +3. 
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A.  
B.  
C.  
Figure 4-10: Release of linked vancomycin. A) Mass spectra after 1 hour soak in 
molecular biology grade water.   B) Mass spectra after 3.5 hour soak C) Mass spectra 
after 24 hour soak.  Peak at 471.3 corresponds to vancomycin with the loss of a chlorine 
and an overall charge to +3. 
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For calcium aluminate with linked vancomycin, the counts observed at 471.3 
were, after 1 hour 370 counts (Figure 4-10A), after 3.5 hours 492 counts (Figure 4-10B), 
and after 24 hours 1132 counts (Figure 4-10C).  Indicating that more vancomycin is 
being released from the sample in which the vancomycin is adsorbed to the substrate 
compared to the linked vancomycin substrates. 
 
4.3.8 Osteoblast Adhesion to Antibiotic Modified Calcium Aluminate 
To determine if any of the modifications increased the number of osteoblasts 
attached to the CA surface when compared to the control, Normal Human Osteoblasts 
(LONZA) were cultured until confluent and diluted to a concentration of 10,000 cells per 
milliliter of media (OGM, LONZA).  Three autoclaved substrates of each type for each 
time period were placed in a 48-well plate and 1mL of cells was added to each well.  
After 1, 4, and 7 days, the number of the cells was determined using the 
Live/Dead/Viability/Cytotoxicity Assay Kit from Invitrogen. Samples were viewed using 
a Zeiss Axioskop 2 under 10x magnification and five images per sample were taken using 
the Zeiss Axiocam. The number of live and dead cells per view was counted using the 
Axiovision 4 Software and the data was normalized to the average number of live or total 
osteoblasts on the unmodified CA at each time point.  Three separate trials were 
completed following the same procedure. The data was then analyzed using one-way 
ANOVA with a Bonferroni post hoc test (p< 0.05) to determine if there were any 
statistical differences between the materials.  
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Figure 4-11: Day 1 one-way ANOVA with Bonferroni post hoc test (p<0.05) live and 
total osteoblast data. C=unmodified CA, A= CA with adsorbed ampicillin, AL= CA with 
ampicillin linked, V= CA with vancomycin adsorbed, VL=CA with vancomycin linked.  
Data represented as mean ± standard error. A) Normalized number of live osteoblasts, * 
=different from C B) Normalized number of total osteoblasts. 
 
On Day 1 the average number of live cells per view (+/- standard deviation) was: 
control CA: 100 ; A: 111.1 ± 68.0; AL: 140.4 ± 81.8; V: 120.7 ± 66.0; VL: 142.6 ± 81.4 
(Figure 4-11A) and the average of total cells per view was: control CA: 100 ; A: 100.2 ± 
55.0; AL: 116.5 ± 63.6; V: 101.0 ± 56.0; VL: 114.1 ± 63.8.(Figure 4-11B)  AL and VL 
had higher numbers of live cells compared to control CA, however no difference was 
seen in the total number of cells.  
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Figure 4-12: Day 4 one-way ANOVA with Bonferroni post hoc test (p<0.05) live and 
total osteoblast data. C=unmodified CA, A= CA with adsorbed ampicillin, AL= CA with 
ampicillin linked, V= CA with vancomycin adsorbed, VL=CA with vancomycin linked.  
Data represented as mean ± standard error. A) Normalized number of live osteoblasts, $ 
=different from C and AL B) Normalized number of total osteoblasts, #=different from 
AL. 
 
On Day 4 the average number of live cells per view was: control CA: 100; A: 146.7 
± 102.6; AL: 100.0 ± 128.3; V: 181.5 ± 114.1; VL: 171.9 ± 128.3 (Figure 4-12A) and the 
average of total cells per view was: control CA: 100; A: 126.7 ± 80.7; AL: 84.1 ± 71.6; 
V: 120.4 ± 63.4; VL: 117.8 ± 83.1. (Figure 4-12B) V and VL had higher numbers of live 
cells compared to control CA and AL.  A had higher total number of cells compared to 
AL.  
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Figure 4-13: Day 7 one-way ANOVA with Bonferroni post hoc test (p<0.05) live and 
total osteoblast data. C=unmodified CA, A= CA with adsorbed ampicillin, AL= CA with 
ampicillin linked, V= CA with vancomycin adsorbed, VL=CA with vancomycin linked.  
Data represented as mean ± standard error. A) Normalized number of live osteoblasts, # 
=different from C and VL B) Normalized number of total osteoblasts, ^=different from 
AL, &=different from C, A, and V. 
 
On Day 7 the average number of live cells per view was: control CA: 100; A: 124.4 
± 140.7; AL: 129.4 ± 110.4; V: 176.7 ± 98.6; VL: 86.7 ± 87.7 (Figure 4-13A) and the 
average of total cells per view was: control CA: 100; A: 105.0 ± 84.3; AL: 81.4 ± 58.4; 
V: 119.7 ± 64.8; VL: 58.8 ± 48.1 (Figure 4-13B).  V had a higher number of live cells 
compared to VL and control CA, and a higher number of total cells compared to AL. VL 
had a lower number of total cells compared to V, A, and control CA. 
 
4.4 Discussion 
Implant associated infections are difficult to eradicate due to their antibiotic 
resistant characteristics. Often the infection is noticed only in very advanced stages where 
removal of the implant is the only therapy available.  For this reason, an antibiotic that 
would be delivered only locally and present immediately after implantation could be 
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advantageous.  In this study, ampicillin and vancomycin were attached to the calcium 
aluminate surface through two different mild methods: adsorption and a three-step 
covalent linkage.  DRIFT confirmed that the antibiotics were attached successfully using 
both methods.  All samples were sterilized by autoclaving before use in any bacteria tests.  
To confirm that autoclaving would not affect the integrity of the modification, DRIFT 
was used to analyze the samples after sterilization and the spectra remain unchanged 
(Data not shown).  Ampicillin is often temperature sensitive so ethanol sterilization and 
no sterilization methods were tested in a zone inhibition assay alongside the standard 
antibiotic and autoclaved samples.  No difference was seen between the sterilization 
methods in antibacterial activity.  
Bacterial turbidity tests showed that both vancomycin modified samples were the 
most effective at inhibiting S. aureus bacterial growth in culture compared to ampicillin 
modified samples (p<0.001). For the two different antibiotic attachment methods utilized 
for vancomycin, no statistical difference in antibacterial activity was found. This 
indicates that the covalent linkage does not affect the antibacterial properties of the 
vancomycin. The vancomycin is linked through one of the two primary amines (NH2 
groups) that are not involved in the hydrogen bonding of vancomycin to the substrate D-
ala-D-ala.  Additionally, both the unmodified disks and ampicillin linked disks inhibited 
bacteria growth in culture. This indicates that the calcium aluminate itself has some 
antibacterial properties. The linkage of the ampicillin through its NH2 group orients it 
actively at the interface in order to inhibit bacterial growth. While the amine group isn’t 
necessary for the antibacterial activity, it does aid in ampicillin’s ability to penetrate the 
cell wall more effectively, thereby likely reducing ampicillin’s effectiveness.17Ampicillin 
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adsorbed to the surface did not inhibit bacterial growth; this may be a result of the 
orientation of the molecule on the surface. For example, the carboxylic acid group or the 
C=O in the four membered ring could be interacting with the oxide surface. This would 
inhibit ampicillin from interacting with the transpeptidases rendering the ampicillin 
inactive. 
15
 
To compare the linked and adsorbed antibiotics to the standard antibiotic dosages, 
a standard zone inhibition assay was done.  The results show that vancomycin linked and 
adsorbed to the disks were as effective as the control dose of the antibiotic.  The adsorbed 
antibiotic was able to travel farther from the disk as evidenced by the larger zone of 
inhibition indicating that it may release faster than the linked counterpart in physiological 
environments. Unmodified disks and both ampicillin modified disks did not produce any 
zones of inhibition.  This was expected as their inhibition of bacteria growth in culture 
was not as significant as vancomycin. 
S. aureus strains often become antibiotic resistant to penicillin-type antibiotics.  
To determine if ampicillin’s inactivity was due to resistant bacteria, the ampicillin 
modified surfaces were tested for antibacterial activity using the gram negative strain E. 
coli.  It was shown that the ampicillin modified surfaces did not inhibit bacterial growth 
in culture or in the zone inhibition assay, indicating that the ampicillin modified surfaces 
are ineffective at inhibiting all bacterial growth. 
Covalent linkage could present a more favorable method of attachment when 
compared to adsorption for biomedical applications.  The linkage of the antibiotic may 
ensure a more local delivery of the antibiotic in physiological environments compared to 
adsorption where the antibiotic could be more easily released into the surrounding tissue 
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or into the bloodstream.  Covalent linkage should also allow for the antibiotic to remain 
at the site of implantation for a longer period of time than adsorption.  ESI-TOF mass 
spectrometry indicated that samples in which the antibiotic was adsorbed released more 
vancomycin at 1 and 24 hours than the samples in which the antibiotic was linked.  After 
3.5 hours, the amount of vancomycin that was released decreased indicating equilibrium 
between the vancomycin on the sample and in the water.  This would not occur in a 
physiological environment, as the antibiotic that was released would be removed from the 
site of implantation through blood flow and would not be in equilibrium on the surface.  
Therefore, covalent linkage of the antibiotic would be more beneficial in physiological 
environments because the activity of the antibiotic did not vary with attachment method. 
Cell adhesion tests indicate that some of the antibiotic modifications increase live 
cells numbers on the CA surface compared to the control but none of the modifications 
increased the total number of cells compared to the control. Also, none of the 
modifications consistently increase cell adhesion at the different time points.  This 
indicates that although overall cell adhesion is not increased by the modifications, they 
increase the viability of the cells on the CA surface and the modifications are therefore 
non-toxic. 
Vancomycin was previously attached to a titanium alloy and was shown to be still 
active in preventing bacterial growth and adhesion to the alloy.
1, 14, 25, 26
  The previously 
reported method involved passivation of the surface with sulfuric acid, multiple wash 
steps in dimethylformamide and three coupling steps. 
1, 14, 25, 26
 The method presented 
here is simple and mild. It involves three-steps that can all be done at low temperatures 
with common solvents and does not require passivation or multiple wash steps.  This 
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method is also applicable to any surface that contains hydroxyl or μ-oxo groups which 
would include the metal-oxide surfaces of common alloys such as SS316L and Ti6Al4V. 
Additionally, any antibiotic or molecule with an NH2 functional group that is not 
involved in its function could be attached through this linker system. 
 
4.5 Conclusions 
Porous calcium aluminate scaffolds were cast at room temperature and ampicillin 
and vancomycin were either adsorbed or covalently linked to the calcium aluminate 
surface using a multi-step solution deposition method.  The covalent linkage system is 
gentle and applicable to any surface that contains reactive hydroxyl or μ-oxo groups. 
Additionally, it can be used with any biomolecule containing an amine group. This 
method is also more beneficial than the other current method to covalently attach 
vancomycin to titanium because of its mild nature.
1, 14, 25, 26
  Unmodified calcium 
aluminate disks and disks with ampicillin linked were able to inhibit S. aureus bacterial 
growth in culture, however, vancomycin either linked or adsorbed to the surface was 
more effective at inhibiting bacterial growth.  It was determined that covalently linking 
the antibiotic to the surface allowed for a smaller more controlled release and would be 
more beneficial than adsorption in a physiological environment.  The antibiotic 
modifications are also non-toxic to osteoblast cells and can increase viability of cells on 
the CA surface. 
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Chapter 5 : Immobilization of Two Bioactive Molecules 
5.1 Introduction 
Current biomaterials are unable to meet the vast demands that a physiological 
environment places on them.  For that reason, many different materials are modified with 
growth factors, antibiotics, and other biomolecules or functionalities to increase the 
biocompatibility and bioactivity of the materials.  These modifications can add beneficial 
properties to the biomaterials, but usually strive to meet one physiological demand that is 
placed on the material and are limited in the amount or type of biomolecules that can be 
attached to the surface.   
 For example, antibacterial coatings are added to decrease biofilm formation on the 
surface of implanted biomaterials.
1-4
  VEGF is attached to increase vascularization 
around or into the implant surface and BMP-2 is used to increase bone formation. Surface 
modifications using cell adhesion peptides are utilized to increase initial cell adhesion.
5-9
  
Most of these studies  used adsorption of the biomolecules to the surface and not covalent 
attachment.
9-14
 This choice may be due to the lack of available functional groups on the 
biomaterial surface for covalent attachment or to the loss of activity of biomolecules that 
can occur if the site of covalent attachment is improperly chosen. 
Most surface modification methods are also only able to attach one specific 
molecule or one class of molecule, unless patterning of the surface is involved.
1-4, 11, 15-20
 
Patterning requires multiple complex steps and only allows for different molecules to be 
immobilized and segregated on the surface.
21
 Some research groups have been able to 
attach two different growth factors, peptides or proteins
5, 7, 8
; however the molecules are 
attached in the exact same manner, or through patterning or gradients which can be 
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difficult to create.
8, 20
 Many immobilization methods require harsh conditions that also 
modify the bulk properties of the material or can leave small amounts of toxic chemicals 
after the biomolecule has been attached. The methods can also take multiple repeats of 
each step which can result in lengthy modification times. 
The goal of this project was to develop an attachment scheme to immobilize both 
an antibiotic (vancomycin) and a cell adhesion peptide (KRSR) that would allow for a 
calcium aluminate surface that both increases osteoblast attachment and decreases 
bacterial growth.  The optimal scheme would have a minimal amount of mild steps 
involved, utilize different functional groups to selectively attach the two different 
biomolecules and allow the biomolecules to retain their activity. 
 
5.2 Materials and Methods 
5.2.1 Materials 
Calcium aluminate aggregates were supplied by Westmoreland Advanced 
Materials.  KRSRC was purchased from Genscript (96.4% purity) as lyophilized powder 
and reconstituted in doubly distilled H2O (ddH2O). Tetrahydrofuran (THF, 99.9% purity), 
methanol (MeOH, Certified ACS, >99.8% pure), Molecular Biology Grade Water 
(Hyclone), and Difco Tryptic Soy Broth were purchased from Thermo Fisher.  THF was 
distilled over sodium and benzophenone before use.  Vancomycin hydrogen chloride 
from Streptomyces orientalis, 1,12-dodecanedicarboxylic acid, N-hydroxysuccinimde, 
12-aminododecanoic acid and Mueller-Hinton 2 agar were purchased from Sigma-
Aldrich.  N’N’-dicyclohexylcarbodiimide was purchased from Fluka. S. aureus strain 
UAMS1 was provided by Allegheny General Singer Center for Genomic Sciences. 
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Normal Human Osteoblasts (NHOsts, CC-2538), osteoblast culturing reagents, and OGM 
media were purchased from LONZA. All materials were used as received unless 
otherwise noted. 3-maleimidopropionic acid N-hydroxysuccinimide (NHS) ester (99%) 
was purchased from Alfa Aesar.   
 
5.2.2 Casting Calcium Aluminate 
Calcium aluminate disks were prepared by a room temperature (20 ºC) cast of 
different sized calcium aluminate aggregates with phases CaAl2O4 and CaAl4O7. The 
aggregates were separated by size during a sifting process in which the cement was 
passed through wire screens of different size meshes and “caught” on another mesh size.  
Three different aggregate sizes (-30 + 60 (25%), -60 (25%), and -325 (50%)) were mixed 
together to form the disks in the casting process. The aggregates were dry mixed at room 
temperature to ensure complete particle distribution.  After dry mixing, doubly-distilled 
H2O was mixed in and the cement paste was allowed to sit for 20 minutes at room 
temperature to thicken.  Upon thickening, the cement was poured into a mold of 8 mm 
diameter disks and allowed to sit overnight.  The phases of the final calcium aluminate 
disks used in the following experiments present in the disks after casting and sterilization 
by autoclaving are: CaAl2O4, CaAl4O7, and Ca3(Al(OH)6)2. 
 
5.2.3 Double Covalent Attachment of Vancomycin and KRSR (VLKL) 
Both vancomycin and KRSR were covalently attached to the calcium aluminate 
surface through a multi-step solution deposition method. First, the calcium aluminate 
disks were immersed in a solution that was 1mM 12-aminododecanoic acid and 1mM 
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1,12-dodecanedicarboxylic acid (THF) for 1 hour at room temperature. Excess solvent 
was removed by placement in a 120ºC oven for 24 hours. The modified disks were placed 
in a 1mM 3-maleimidopropionic acid NHS ester in acetonitrile solution for 24 hours.  
The solvent was removed by vacuum (0.1 Torr) for 24 hours.  The substrates were then 
placed in a solution that was 2mM N’N’-dicyclohexylcarbodiimide (DCC) and 2mM N-
hydroxysuccinimide (NHS) in dry THF for 24 hours.  The solvent was removed by 
vacuum (0.1 Torr) for 24 hours.  The disks were dipped in a 1 mg/mL solution 
vancomycin in methanol (MeOH) at 30 ºC for 24 hours, and dried under vacuum for 
24 hours.  Finally the samples were dipped in a 1 mg/mL solution of KRSR(C) in ddH2O 
at 4ºC for 24 hours, and dried under vacuum for 24 hours. Scheme 5-1 shows a schematic 
representation of the VLKL attachment method. Samples were sterilized by autoclaving 
at 121 ºC and 18 psi of steam for 60 min with fast exhaust prior to antibiotic and cell 
adhesion testing. 
 
Scheme 5-1: Schematic representation of the five-step covalent VLKL attachment of 
both vancomycin and KRSR.  1. 3-maleimidopropionic acid NHS ester (ACN) 2. 
DCC/NHS (THF) 3. Vancomycin (MeOH) 4. KRSR(C) (ddH2O). 
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5.2.4 Double Covalent Attachment of KRSR and Vancomycin (KLVL) 
A second method for covalently attaching both KRSR and vancomycin to the 
surface was utilized to investigate any loss of activity due to the order of biomolecule 
attachment. First, the calcium aluminate disks were immersed in a solution that was 1mM 
12-aminododecanoic acid and 1mM 1,12-dodecanedicarboxylic acid (THF) for 1 hour at 
room temperature. Excess solvent was removed by placement in a 120º C oven for 24 
hours. The modified disks were placed in 1mM 3-maleimidopropionic acid NHS ester in 
acetonitrile solution for 24 hours.  The solvent was removed by vacuum (0.1 Torr) for 
24 hours.  The substrates were placed in a solution that was 2mM N’N’-
dicyclohexylcarbodiimide (DCC) and 2mM N-hydroxysuccinimide (NHS) in dry THF 
for 24 hours.  The solvent was removed by vacuum (0.1 Torr) for 24 hours.  The samples 
were then dipped in a 1 mg/mL solution of KRSR(C) in ddH2O at 4ºC for 24 hours, and 
dried under vacuum for 24 hours. Finally, the disks were dipped in a 1 mg/mL solution 
vancomycin in methanol (MeOH) at 30 ºC for 24 hours, and dried under vacuum for 
24 hours.  Scheme 5-2 shows a schematic representation of the KLVL attachment 
method. Samples were sterilized by autoclaving at 121 ºC and 18 psi of steam for 60 min 
with fast exhaust prior to antibiotic and cell adhesion testing. 
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Scheme 5-2: Schematic representation of the five-step covalent attachment of both 
vancomycin and KRSR.  1. 3-maleimidopropionic acid NHS ester (ACN) 2. DCC/NHS 
(THF) 3. KRSR(C)(ddH2O) 4. Vancomycin (MeOH). 
 
5.2.5 Covalent Attachment of KRSR and Adsorption of Vancomycin 
(KLVA) 
A third method of attachment in which the peptide KRSR was covalently attached 
and the antibiotic vancomycin was adsorbed was used to ensure that the addition of the 
antibiotic to the peptide modified surface did not cause loss of activity of the peptide. 
First, the substrates were placed in a 1mM 12-aminododecanoic acid in dry 
tetrahydrofuran (THF) solution at room temperature for one hour. The excess solvent was 
removed by placement in a 120 ˚C oven for 24 hours.  The 12-aminododecanoic acid 
modified CA disks were placed in a 1mM 3-maleimidopropionic acid NHS ester in 
acetonitrile solution for 24 hours.  The solvent was removed by vacuum (0.1 Torr) for 
24 hours.  The substrates were dipped in a 1 mg/mL solution of KRSR(C) in ddH2O at 4 
ºC for 24 hours and dried under vacuum for 24 hours. Finally, the disks were dipped in a 
1 mg/mL solution vancomycin (MeOH) at room temperature for 24 hours, and dried 
under vacuum for 24 hours.  Scheme 5-3 shows a schematic representation of the KLVA 
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double modification method. Samples were sterilized by autoclaving at 121 ºC and 18 psi 
of steam for 60 min with fast exhaust prior to antibiotic and cell adhesion testing. 
 
Scheme 5-3: Schematic representation of the four-step covalent attachment of KRSR 
followed by vancomycin adsorbed to the surface in the 4
th
 step. 
 
5.2.6 Diffuse Reflectance Infrared Fourier Transform Spectroscopy 
A Thermo Nicolet Nexus 470 FT-IR Spectrophotometer equipped with a diffuse 
reflectance attachment was used to obtain the spectra of the substrates after each 
deposition step. Spectra were collected with 256 scans and a resolution of 4 cm
-1
. 
 
5.2.7 Staphylococcus aureus Bacterial Turbidity Tests 
A standard optical density analysis of bacterial growth was used to determine the 
antibiotic activity of vancomycin attached on the calcium aluminate surface against gram 
positive bacteria. S. aureus (UAMS1) was diluted to 0.1 optical density at 600 nm 
(OD600nm) in Tryptic soy broth with 0.1 M NaCl and 0.08 % glucose.  Two milliliters of 
the bacterial suspension was placed in with each type of sample. There were five samples 
of each type in each trial for three separate trials. Samples were incubated at 37 ºC and 5 
% CO2 for 3.5 hours.  The disks were then removed from the bacterial solution and the 
optical density at 600 nm was recorded. Statistical analysis of the average optical density 
at 600 nm was done using Origin 8.0 using a one-way ANOVA with a Bonferroni post 
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hoc test (p<0.05 and p<0.001).  The sample groups were: no disk (B, bacteria only), 
VLKL, KLVL and KLVA.   A set of control vancomycin 30µg disks (VS) was also 
tested to compare to the vancomycin modified samples. 
 
5.2.8 Staphylococcus aureus Zone Inhibition Assay 
A standard zone inhibition assay was used to determine the activity of the 
antibiotic attached to the calcium aluminate surface compared to the standard antibiotic. 
S. aureus (UAMS1) was diluted to 0.1 OD600nm in Tryptic soy broth with 0.1 M NaCl and 
0.08 % glucose and spread onto Mueller-Hinton 2 Agar plates with cotton swabs.  The 
plate set up for the vancomycin assay was: a standard disk of 30 µg of vancomycin (VS) 
was placed in the upper left quadrant of the plate, and then one each of the following 3 
samples types VLKL, KLVL, KLVA was placed in the remaining quadrants. Plates were 
incubated agar side down (to ensure samples did not displace) for 24 hours at 37 ºC and 5 
% CO2.  The diameter of the zone with the absence of bacterial growth was then 
measured in millimeters. Statistical analysis was done using a one-way ANOVA with 
Bonferroni post hoc test (p<0.05) to determine any differences in the diameters of the 
zones of inhibition. 
 
5.2.9 Osteoblast Adhesion to Double Modified Calcium Aluminate 
Normal human osteoblasts isolated from a 6 and 11 year old female and 
purchased from LONZA (NHOsts) were cultured until confluent and diluted to a 
concentration of 10,000 cells per one milliliter of media (OGM media, LONZA).  Three 
of each type of substrate per time point was placed in a 48-well plate and 1mL of cells 
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was added to each well.  After 1, 4, and 7 days, the number of cells was determined using 
the Live/Dead/Viability/Cytotoxicity Assay Kit from Invitrogen by counting the number 
of live (green) versus dead (red) cells.  Five spots on each sample with an area of 0.6 
mm
2
 were imaged under 10x magnification using the Axioskop2.  Three separate trials 
were completed with a total of 9 samples of each type with a total of 45 views for each 
sample type at each time point. The data was then normalized to the number of live or 
total cells on the unmodified CA at each time point and statistical analysis was done 
using Origin 8.0 using a one-way ANOVA with a Bonferroni post hoc test (p<0.05).   
 
5.3 Results 
5.3.1 DRIFT Spectroscopy of KRSR and Vancomycin Attachment 
To increase cell adhesion and the antibacterial properties of the calcium aluminate 
surface simultaneously, the cell adhesion peptide KRSR and the antibiotic vancomycin 
were covalently attached to the CA surface. To immobilize the biomolecules on the CA 
surface, samples VLKL and KLVL were immersed in a 1mM 12-aminododecanoic acid/ 
1mM 1,12-dodecanedicarboxylic acid solution (THF) for one hour at room temperature.  
Samples were removed from solution and placed in a 120°C oven overnight.  The 
samples were analyzed using Diffuse Reflectance Infrared Fourier Transform 
Spectroscopy (DRIFT) and the presence of the CH2 asymmetric and CH2 symmetric 
stretches at 2922 and 2851 cm
-1
, respectively, in the spectrum indicated that the acids had 
been attached to the surface (Figure 5-1A).  For KLVA, these peaks were also indicative 
of the 12-aminododecanoic acid being present on the surface. Next, all three types of 
samples (KLVA, VLKL, and KLVL) were placed in a 1mM solution of 3-
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maleimidopropionic acid N-hydroxysuccinimide ester for 24 hours at room temperature. 
The ester bond of the 3-maleimidopropionic acid N-hydroxysuccinimide was broken and 
an amide bond was formed between the 12-aminododecanoic acid on the surface and the 
3-maleimidopropionic acid while the COOH tail group of the 1,12-dodecanedicarboxlyic 
acid remains unreacted in the VLKL and KLVL samples.   
 
Figure 5-1: DRIFT spectra for each step of peptide attachment. A) CH stretch region 
showing the CH2 symmetric and asymmetric stretches from the carbon chains of the 
organic acids to the CA surface.  B) The peak at 1711cm
-1 
from the C=O stretches of the 
imide ring of 3-maleimidopropionic acid NHS ester. C) Peak changes from 1800 to 1000 
cm
-1
 are assigned to the carbonyl bond stretches present on the succinimide ring. D) The 
appearance of a peak at 1230 cm
-1
 in the vancomycin attachment is from the amine 
groups present in the vancomycin structure. E) The peaks at 760 and 714 cm
-1
 due to the 
formation of the C-S bond from the Michael addition of the cysteine residue to the imide 
ring. 
 
The samples were removed from solution and placed on a vacuum line (0.1 Torr) 
to remove any excess solvent. DRIFT was used to analyze the samples and the peaks in 
the spectrum at 1792 and 1714 cm
-1
 were assigned to the carbonyl bond stretches present 
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on the imide ring and indicated that it had been successfully attached to the carbon chain 
(Figure 5-1B).  The KLVL and VLKL samples were placed in a 2mM N’N’-
dicyclohexylcarbodiimide (DCC)/ 2mM N-hydroxysuccinimide (NHS) solution in dry 
THF for 24 hours at room temperature. The samples were removed from solution and 
placed on a vacuum line (0.1 Torr) to remove any excess solvent. The DCC reacted first 
with the COOH tail group and was displaced by the NHS. The DRIFT results for this step 
of the attachment (red) showed a change from the previous modification step’s spectrum 
(in blue) from 1800 to 1000 cm
-1
due to the changes in the carbonyl stretching region of 
the spectrum that are a result of the carbonyl groups present on the succinimide ring 
indicating it had been successfully attached (Figure 5-1C). 
For VLKL, vancomycin was attached in the fourth step by immersing the samples 
in a in a 1 mg/ mL solution the antibiotic for 24 hours at 4 °C. The NHS was displaced 
and an amine group on the antibiotic reacted with O
-
forming an amide bond.  The 
samples were removed from solution and placed on the vacuum line overnight. 
Vancomycin immobilization was confirmed by the appearance of a peak at 1230 cm
-1
 
which was attributed to the amine groups present in the vancomycin structure (Figure 
5-1D). KRSR(C) was immobilized in the fifth step by immersing the samples in a 
1mg/mL solution of the peptide for 24 hours at 4°C where the cysteine terminated 
peptide went through a Michael addition to the imide ring.  The samples were removed 
from solution and placed on the vacuum line overnight. The appearance of peaks at 760 
and 714 cm
-1
were due to the C-S bond stretch indicating that the Michael addition had 
occurred through the cysteine residue and the peptide had been attached to the surface 
(Figure 5-1E). 
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For the KLVL samples, KRSR(C) was attached in the fourth step by immersing 
the samples in a 1 mg/mL solution of KRSR(C) for 24 hours at 4 ºC where the cysteine 
terminated peptide went through a Michael addition to the imide ring.  The samples were 
removed from solution and placed on the vacuum line overnight. The appearance of 
peaks at 760 and 714 cm
-1
were due to the C-S bond stretch from which indicated that the 
Michael addition had occurred through the cysteine residue and the peptide had been 
attached to the surface (Figure 5-1E).  Vancomycin was attached in the fifth step by 
immersing the samples in a in a 1 mg/ mL solution the antibiotic for 24 hours at 4 °C. 
The NHS was displaced and an amine group on the antibiotic reacted with O
-
forming an 
amide bond.  The samples were removed from solution and placed on the vacuum line 
overnight. Vancomycin immobilization was confirmed by the appearance of a peak at 
1230 cm
-1
 which was attributed to the amine groups present in the vancomycin structure 
(Figure 5-1D). 
For KLVA, the KRSR(C) was attached in the third step by placing the samples in 
a 1 mg/mL solution of the peptide in ddH2O for 24 hours at 4 ºC.  The excess solvent was 
removed by vacuum for 24 hours.  The peaks due to the C-S bond stretch are used to 
determine the KRSR(C) peptide has been successfully immobilized (Figure 5-1E).  The 
samples are then immersed in a 1mg/mL solution of vancomycin in methanol at room 
temperature for 24 hours and the excess solvent is removed by placement on a vacuum 
line at 0.1 Torr.  The peak at 1230 cm
-1
  is used to determine the adsorption of 
vancomycin on the surface and is assigned to the amine groups present in the vancomycin 
structure (Figure 5-1D). 
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5.3.2 Staphylococcus aureus Bacterial Turbidity Test 
Antibiotic activity in culture was determined by a standard optical density test for 
bacteria. S. aureus (UAMS1) was diluted to an optical density of 0.1 (at 600 nm).  Two 
milliliters of the bacterial solution was placed in a 15mL centrifuge tube with each of the 
samples.  Three trials with 5 samples each of a bacteria solution with no sample (B), 
KLVA, VLKL, and KLVL, and one trial of 5 samples of the 30µg standard vancomycin 
disk (VS) were incubated for 3.5 hours with a 0.1 OD600nmS . aureus(UAMS1) bacteria 
solution Tryptic soy broth with 0.1 M NaCl and 0.08 % glucose at 37°C. 
 
Figure 5-2: Bacteria Turbidity Trials with S. Aureus. At p<0.05, * is different from B. At 
p<0.001 $ is different from B and VLKL; ^ is different than B, VS, and VLKL. In this 
case “different from” indicates it has a statistically lower optical density or less bacteria 
in solution. (Represented as mean ± standard error). 
 
 After 3.5 hours, the sample disks were removed and the optical densities were 
(mean ± standard deviation): VS = 0.269 ± 0.006; B = 0.459 ± 0.032; KLVA = 0.186 ± 
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0.009; VLKL = 0.430 ± 0.037; KLVL = 0.186 ± 0.012. One-way ANOVA with 
Bonferroni post hoc test was used to determine statistical significance (Figure 5-2).  At p 
< 0.05, VLKL decreased bacteria growth compared to B.  At p < 0.001 VS decreased 
bacteria growth compared to B and VLKL; and KLVL and KLVA significantly 
decreased bacteria growth compared to B, VS, and VLKL. There was no statistical 
difference between KLVA and KLVL. 
 
5.3.3 Staphylococcus aureus Zone Inhibition Assays 
To determine the effectiveness of the antibiotic on the CA surface when compared 
to a control dosage (30 µg of vancomycin) of the antibiotic, a zone inhibition assay was 
used.  S. aureus (UAMS1) was diluted to 0.1 OD600nm in Tryptic soy broth with 0.1 M 
NaCl and 0.08 % glucose and spread onto Mueller-Hinton 2 Agar plates with cotton 
swabs.  Five plates for each antibiotic were used for each trial with a total of four trials 
for VS, KLVA and VLKL and three trials of KLVL.  Each plate contained one of each 
type of disk. Plates were incubated agar side down (to ensure samples did not displace) 
for 24 hours at 37 °C and 5 % CO2.  The diameter of the zone with the absence of 
bacterial growth was then measured in millimeters. 
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Figure 5-3:Zone Inhibition Assay. * At p<0.05, VLKL had a statistically smaller zone of 
inhibition than all other samples. At p<0.05 KLVA and KLVL were as effective at killing 
bacteria as the vancomycin standard (VS). (Represented as mean ± standard error). 
 
 The zones of inhibition were (mean ±standard deviation):    VS = 18.4 ± 1.0 mm; 
KLVA = 17.9 ± 1.60 mm; VLKL = 14.4 ± 2.50; and KLVL = 18 ± 3.1 mm. One-way 
ANOVA with Bonferroni post hoc test was used to determine statistical significance 
(Figure 5-3).  At p < 0.05 VLKL had a statistically significantly smaller zone of 
inhibition compared to all other samples, however KLVA and KLVL were as effective at 
inhibiting bacteria growth as the standard VS disk. 
 
5.3.4 Osteoblast Adhesion to Double Modified Calcium Aluminate 
To determine if any of the modifications increased the number of osteoblasts 
attached to the CA surface when compared to the control, Normal Human Osteoblasts 
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(LONZA) were cultured until confluent and diluted to a concentration of 10,000 cells per 
milliliter of media (OGM, LONZA).  Three autoclaved substrates of each type for each 
time period were placed in a 48-well plate and 1mL of cells was added to each well.  
After 1, 4, and 7 days, the number of the cells was determined using the Live/Dead/ 
Viability/Cytotoxicity Assay Kit from Invitrogen. Samples were viewed using a Zeiss 
Axioskop 2 under 10x magnification and five images per sample were taken using the 
Zeiss Axiocam. The number of live and dead cells per view was counted using the 
Axiovision 4 Software.  Three separate trials were completed following the same 
procedure. The data at each time point was then normalized to the average number of live 
or total osteoblasts on the unmodified CA and analyzed using one-way ANOVA with a 
Bonferroni post hoc test (p < 0.05) to determine if there were any statistical differences 
between the materials.  
On Day 1 the normalized average number of live cells per view (+/- standard 
deviation) was: control CA: 100; KLVA: 196.1 ± 76.3; VLKL: 253.3 ± 128.1; KLVL: 
321.1 ± 132.9 (Figure 5-4) and the average of total cells per view was: control CA: 100; 
KLVA: 128.9 ± 48.9; VLKL: 159.0 ± 79.6; KLVL: 200.3 ± 77.4 (Figure 5-5).  Statistical 
analysis indicated that KLVA had a higher number of live cells than the control; VLKL a 
higher number of live cells than the control and KLVA and more total cells than the 
control; and KLVL had more live cells and total cells than all other samples. 
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Figure 5-4:Live Day 1 Osteoblast Attachment. One-way ANOVA with Bonferroni post 
hoc test at p<0.05, * is different from C; $ is different from KLVA and C; # is different 
from all other samples. Data represented as mean ± standard error. C = unmodified CA; 
KLVA = KRSR(C) attached first then vancomycin adsorbed; VLKL = attachment with 
vancomycin attached first followed by KRSR(C); KLVL = attachment with KRSR(C) 
attached first followed by vancomycin. 
 
 
 
Figure 5-5:Total Day 1 Osteoblast Attachment. One-way ANOVA with Bonferroni post 
hoc test at p<0.05, * is different from C; $ is different from KLVA and C; # is different 
from all other samples. Data represented as mean ± standard error. C = unmodified CA; 
KLVA = KRSR(C) attached first then vancomycin adsorbed; VLKL = attachment with 
vancomycin attached first followed by KRSR(C); KLVL = attachment with KRSR(C) 
attached first followed by vancomycin. 
120 
 
 
 
Figure 5-6:Live Day 4 Osteoblast Attachment. One-way ANOVA with Bonferroni post 
hoc test at p<0.05, * is different from C; $ is different from KLVA and C; # is different 
from all other samples; ^ is different from KLVA. Data represented as mean ± standard 
error. C = unmodified CA; KLVA = KRSR(C) attached first then vancomycin adsorbed; 
VLKL = attachment with vancomycin attached first followed by KRSR(C); KLVL = 
attachment with KRSR(C) attached first followed by vancomycin. 
 
On Day 4 the average number of live cells per view (+/- standard deviation) was: 
control CA: 100; KLVA: 99.6 ± 65.3; VLKL: 139.1 ± 68.0; KLVL: 189.8 ± 83.6 (Figure 
5-6) and the average of total cells per view was: control CA: 100; KLVA: 74.2 ± 47.0; 
VLKL: 103.1 ± 48.4; KLVL: 127.2 ± 54.8 (Figure 5-7).  
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Figure 5-7:Total Day 4 Osteoblast Attachment. One-way ANOVA with Bonferroni post 
hoc test at p<0.05, * is different from C; $ is different from KLVA and C; # is different 
from all other samples; ^ is different from KLVA.  Data represented as mean ± standard 
error. C = unmodified CA; KLVA = KRSR(C) attached first then vancomycin adsorbed; 
VLKL = attachment with vancomycin attached first followed by KRSR(C); KLVL = 
attachment with KRSR(C) attached first followed by vancomycin. 
 
Statistical analysis indicated that KLVA had significantly less live cells than all 
other samples; VLKL had a higher number of live cells than the control and KLVA and 
more total cells than KLVA; and KLVL had a higher number of live cell than all other 
samples and a higher number of total cells than KLVA and the control. 
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Figure 5-8:Live Day 7 Osteoblast Attachment. One-way ANOVA with Bonferroni post 
hoc test at p<0.05, * is different from C; $ is different from KLVA and C; # is different 
from all other samples; ^ is different from KLVA. Data represented as mean ± standard 
error. C = unmodified CA; KLVA = KRSR(C) attached first then vancomycin adsorbed; 
VLKL = attachment with vancomycin attached first followed by KRSR(C); KLVL = 
attachment with KRSR(C) attached first followed by vancomycin. 
 
On Day 7 the average number of live cells per view (+/- standard deviation) was: 
control CA: 100; KLVA: 78.7 ± 52.5; VLKL: 147.6 ± 149.0; KLVL: 245.3 ± 123.9 
(Figure 5-8) and the average of total cells per view was: control CA: 100; KLVA: 64.2 ± 
35.8; VLKL: 96.5 ± 93.1; KLVL: 146.7 ± 67.6 (Figure 5-9). Statistical analysis indicated 
that KLVA had significantly less total cells than the control; VLKL had significantly 
more live cells than KLVA; and KLVL had significantly more live and total cells than all 
other samples. 
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Figure 5-9:Total Day 7 Osteoblast Attachment. One-way ANOVA with Bonferroni post 
hoc test at p<0.05, * is different from C; $ is different from KLVA and C; # is different 
from all other samples; ^ is different from KLVA. Data represented as mean ± standard 
error. C = unmodified CA; KLVA = KRSR(C) attached first then vancomycin adsorbed; 
VLKL = attachment with vancomycin attached first followed by KRSR(C); KLVL = 
attachment with KRSR(C) attached first followed by vancomycin. 
 
 
5.4 Discussion 
To increase the osteoblast adhesion on the calcium aluminate surface while 
simultaneously decreasing the bacterial attachment, both KRSR and vancomycin were 
immobilized on the surface.  Three different attachment schemes were utilized to ensure 
that both biomolecules remained active and to determine the best order of attachment for 
optimal osteoblast adhesion and antibacterial activity. 
The first attachment scheme used was the VLKL method.  This scheme was 
designed to have the fewest possible deposition steps, and to attach the peptide in the 
final step in case the vancomycin attachment conditions were too harsh for the peptide 
and the activity of the peptide was lost.  The KLVL method was then developed to 
evaluate the activity of both biomolecules when the peptide was attached first and the 
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final step of attachment was the addition of vancomycin.  This scheme was designed to 
also have the minimal amount of deposition steps, but the reverse of the last two steps of 
the VLKL method was to evaluate the effect immobilization order had on the activity of 
the biomolecules.  The final attachment method, KLVA, was designed as a comparison 
method to further evaluate the effectiveness of adsorption versus covalent attachment for 
the antibiotic as well as a comparison for the success of the first two schemes in attaching 
both biomolecules in comparable amounts. DRIFT analysis after each step of 
immobilization confirmed that both biomolecules were successfully attached utilizing all 
three attachment methods. 
Bacterial turbidity tests with S. aureus indicate that VLKL is successful at 
inhibiting bacterial growth in culture (p < 0.05), however it is not as effective as the 
standard dosage, VS, (p < 0.001). Both KLVL and KLVA were more effective than the 
standard dosage and VLKL at inhibiting bacterial growth in culture.  Similar results were 
seen in the zone inhibition assay in which VLKL had a statistically significantly smaller 
zone of inhibition than VS, KLVL and KLVA, and no statistical significance was seen 
between the other 3 samples.  This indicates that VLKL is the least effective in inhibiting 
bacterial growth in culture. The decrease in activity of VLKL over the other samples is 
most likely due to the interaction of the peptide with the antibiotic during deposition.  
Vancomycin interacts with D-ala-D-ala termini of the growing bacterial peptidoglycan 
cell wall by hydrogen bonding to oxygen and hydrogens mainly from the backbone of the 
peptide.  Results from the single modification of CA with vancomycin indicate that the 
antibiotic is linked to the surface with its active site that interacts with the D-ala-D-ala 
substrate oriented away from the surface, open at the interface.
23
 Therefore, when the 
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KRSR(C) peptide is immobilized after the vancomycin has been immobilized to the 
surface, the peptide may be non-specifically interacting and hydrogen bonding to the 
active site of vancomycin inhibiting its ability to interact with the natural substrate thus 
decreasing its antibacterial activity relative to the other two sample types.  
Osteoblast adhesion studies showed that on Day 1, all three modification schemes 
were successful in increasing live cell adhesion compared to the unmodified CA surface. 
However, KLVL significantly increased live and total cell adhesion compared to all other 
sample types. On Day 4, KLVL increased live cell adhesion compared to all other 
samples types and increased total cell adhesion compared to unmodified CA and KLVA. 
On Day 7, KLVL again increased both live and total cell adhesion compared to all 
sample types.  The osteoblast adhesion results indicate that the KLVL attachment method 
is the most successful at increasing osteoblast adhesion on the CA surface.  The VLKL 
and KLVA methods are also able to increase cell adhesion at some time points; however 
they are not as successful as the KLVL method.  The interaction between vancomycin 
and KRSR(C) that decreased the antibacterial activity of the vancomycin in the bacterial 
tests is also the cause of the decreased activity of KRSR(C) to increase cell adhesion in 
the VLKL and KLVA samples.  The hydrogen bonding interaction between vancomycin 
and KRSR(C) would inhibit the ability of the peptide to properly interact with the 
osteoblast proteoglycans. 
The results from the bacterial and osteoblast tests indicate that all three sample 
types could be viable options for decreasing bacterial adhesion.  However, the optimal 
attachment method for both increasing osteoblast adhesion and decreasing bacterial 
adhesion is the KLVL method in which KRSR(C) is immobilized in the 4
th
 step and the 
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vancomycin is immobilized in the 5
th
 step.  This attachment method resulted in modified 
calcium aluminate samples that optimally increased osteoblast attachment and decreased 
bacterial growth. 
 
5.5 Conclusions 
Porous calcium aluminate scaffolds were cast at room temperature and three 
different schemes were successfully used to attach both vancomycin and KRSR to the 
calcium aluminate surface using multi-step solution deposition methods.  DRIFT was 
used to confirm all steps were successful in each of the 3 attachment methods.  KLVA 
and KLVL were more effective than the standard dosage of the antibiotic reducing S. 
aureus growth in culture.  In the zone inhibition tests, KLVA and KLVL produced zones 
of inhibition comparable to the standard dosage; however VLKL produce a significantly 
smaller zone.  Osteoblast cell adhesion tests indicated that although all three sample types 
were able to increase live and total cell adhesion on CA at least one of the time points, 
KLVL was able to increase live and total cell adhesion compared to all sample types on 
Days 1 and 7 and compared to most sample types on Day 4.  It was determined that the 
optimal attachment method to increase cell adhesion and decrease bacterial growth was 
KLVL. 
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Chapter 6 : Conclusions 
6.1 Physical Optimization of Calcium Aluminate 
The physical properties of the calcium aluminate material were modified and 
optimized for use as a bone scaffold material through the casting procedure.  Five 
different mixtures (A-E) were created by varying the ratio of the starting material 
aggregates and then subjecting the mixtures to one of four different heat treatments.  The 
average pore sizes of the material were determined by optical microscopy and ranged 
from approximately 100 to 290 microns. The heat treatments did not affect the average 
pore size of the material.  The two mixtures with the largest pore sizes were eliminated 
for further analysis due to their lack of mechanical strength.  
The three remaining Mixtures A, B, and C that had been subjected to the four heat 
treatments were then analyzed using a four point bend (modulus of rupture) and a cold 
crushing test for their mechanical strength.  It was found that the smaller the average pore 
size of the mixture was, the greater the modulus of rupture and cold crushing strength of 
the material were.  It was also determined that dry heat treatments at 650 º C decrease the 
strength of the material whereas autoclaving (a wet heat treatment) increased the modulus 
of rupture of the material.   
Mixtures A-C were evaluated for their biological properties.  The degradation in 
phosphate buffered saline was evaluated and all mixtures were found to be stable for up 
to 6 months.  They were also evaluated for cell adhesion on Days 1, 4, and 7 and it was 
found that on Day 4, Mixture A with an average pore size of approximately 100 µm 
increased cell adhesion compared to Mixtures B and C.   
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After reviewing the results of the various physical and biological tests, Mixture A 
was chosen over Mixtures B and C for the remaining studies due to the increased strength 
of the material as well as the increased cell adhesion on Day 4.  This project determined 
that the optimal pore size of the material was approximately 100 µm and that autoclaving 
was an acceptable sterilization method for the calcium aluminate material due to its 
impact on increasing the strength of the material. 
 
6.2 Immobilization and Effect of Cell Adhesion Peptides 
The surface of Mixture A was successfully covalently modified with cell adhesion 
peptides through a three-step solution deposition method.  Diffuse Reflectance Infrared 
Fourier Transform Spectroscopy confirmed cell adhesion peptides RGD and KRSR with 
added terminal cysteine residues were attached to the CA surface. The peptide modified 
surfaces were then evaluated for their biological activity through cell adhesion tests, cell 
proliferation tests, and Scanning Electron Microscopy. 
Fibroblast test results indicated that both RGD and KRSR increased live fibroblast 
adhesion on CA when compared to the control unmodified CA.  Osteoblast tests showed 
that KRSR increased live osteoblast adhesion compared to all other samples and also 
increased live osteoblast adhesion compared to fibroblast adhesion on Days 1 and 4.  
KRSR modified CA increases total osteoblast adhesion compared to unmodified CA and 
compared to RGD modified CA on Days 1 and 4. These results show that KRSR would 
be more beneficial in bone regenerating applications than RGD because it is cell-specific 
to osteoblasts whereas RGD in a non-cell specific peptide. 
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Finally, the effect of KRSR on osteoblast morphology was evaluated using SEM.  
RGD does not allow for cell spreading unless combined with another cell adhesion 
peptide, PHSRN, so it was important to determine if the immobilization of the KRSR cell 
adhesion peptide alone could increase cell spreading on the CA surface. SEM images 
showed that the osteoblasts present on the unmodified CA surface were rounded whereas 
the osteoblasts that were present on the KRSR modified surface were spread.  Cell 
spreading is necessary for cell proliferation and the addition of the KRSR peptide to the 
CA surface increased cell spreading which would increase cell proliferation that is 
necessary for tissue regeneration   
After reviewing the results of all of the cell adhesion peptide tests, it was concluded 
that immobilizing the KRSR cell adhesion peptide onto the CA surface preferentially 
increased osteoblast adhesion over fibroblast adhesion and increased osteoblast 
spreading. Therefore, KRSR was the most beneficial cell adhesion peptide for optimizing 
CA as a bone scaffold material 
 
6.3 Immobilization and Effect of Antibiotics 
The surface of Mixture A was successfully covalently modified with antibiotics 
using a three-step solution deposition method. DRIFT spectroscopy confirmed that 
vancomycin and ampicillin were attached to the CA surface.  Both antibiotics were also 
successfully adsorbed onto the CA surface in a one-step solution deposition method 
which was also confirmed by DRIFT spectroscopy.  The activity of vancomycin which is 
effective against gram-positive bacteria was determined using S. aureus, a common 
gram-positive bacteria found in implant related infections.  The activity of ampicillin, 
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which is effective against gram-positive and some gram-negative bacteria was 
determined using S. aureus and E.coli, a gram-negative bacteria associated with some 
implant infections and also other common infections. S. aureus bacterial turbidity results 
indicated that unmodified CA and CA with adsorbed or covalently linked vancomycin 
inhibited bacterial growth in culture.  These results show that CA has some inherent 
antibacterial activity that would be beneficial in an implant material and help reduce 
infection without any type of added antibiotic therapy. The bacterial turbidity results 
along with the zone inhibition results also showed that the vancomycin modified samples 
were more effective than a standard dose of vancomycin at inhibiting bacterial growth.   
 Based on the antibacterial activity data, it was determined that CA modified with 
vancomycin, either covalently or adsorbed onto the surface, was the most effective at 
inhibiting bacterial growth. Linking or adsorbing the antibiotics on the surface of an 
implant would decrease the need for prescribed systemic antibiotics after surgery.  This is 
extremely beneficial as it would decrease bacterial resistance to antibiotic because the 
required dosages would be smaller. 
Based on the mass spectrometry data, vancomycin that was covalently linked to 
the CA surface released slower than the vancomycin that was adsorbed to the CA surface.  
This is because adsorption is a weaker physical interaction that is susceptible to shear 
flow and diffusion whereas the covalent linkage is much stronger and less susceptible to 
these release methods.  These results combined with the comparable antibacterial activity 
of both samples in the S. aureus tests indicated that covalently linking the antibiotic 
would be more beneficial in a physiological environment by releasing the antibiotic more 
slowly and allowing it to be at the site of implantation for longer periods of time.  
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Covalently linking the antibiotic also prevents the vancomycin from diffusing to other 
tissues thus reducing bacterial resistance to antibiotics by reducing systemic delivery. 
Finally to determine the biocompatibility of all modifications, all antibiotic 
modified samples and unmodified CA were incubated with osteoblasts for 1, 4 and 7 
days.  It was found no modifications decreased live cell attachment and therefore are non-
toxic and acceptable for use in bone scaffold applications. 
 
6.4 Immobilization of Two Bioactive Molecules 
KRSR and vancomycin were the most effective surface modifications to the 
physically optimized CA to increase osteoblast adhesion and inhibit S. aureus bacterial 
growth.  Three different schemes were develop to simultaneously immobilize both 
biomolecules onto the CA surface.  Two of the schemes covalently attached both 
biomolecules and utilized the same first three steps for the immobilization process.  
Following the third step, the VLKL attachment method, then attached vancomycin in the 
fourth step, followed by KRSR in the fifth step.  The KLVL attachment method attached 
KRSR in the fourth step followed by vancomycin in the fifth.  The third and final double 
immobilization scheme, KLVA, linked KRSR to the surface following the protocol for 
immobilization of a single cell adhesion peptide, followed by adsorption of vancomycin 
onto the peptide modified surface.  The three different schemes were utilized to 
investigate any loss in activity of either biomolecule that could be due to the order in 
which the two biomolecules were attached.  DRIFT confirmed that the attachment of both 
biomolecules was successful under all three attachment schemes. After confirming that 
the three attachment methods were successful, the bioactivity of both biomolecules was 
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evaluated utilizing the experiments that had been completed to determine the activity of 
the single biomolecule modification. 
Bacterial turbidity and zone inhibition tests showed that KLVL and KLVA were 
more effective than VLKL and the standard vancomycin dosage at inhibiting bacteria 
growth. Osteoblast tests results showed that KLVL increased live and total osteoblast 
adhesion more effectively than the other two double immobilization schemes. Based on 
these results, the activity of both biomolecules is affected by the order in which they are 
immobilized.  In this case, if KRSR if immobilized after the vancomycin, it interacts with 
the active site of the antibiotic and inhibits its ability to reduce bacteria growth.  A similar 
effect is seen when KRSR is individually linked to the surface followed by adsorption of 
vancomycin.  The KLVL attachment scheme allows both biomolecules to be present at 
the CA surface in an effective and active form to increase osteoblast adhesion and 
decrease bacteria growth and is the optimal double immobilization scheme for the CA 
surface. 
 
6.5 Impact and Future Directions 
During the course of this project, the CA material was physically optimized for use 
as a bone scaffold material.  The single immobilization of the antibiotic, vancomycin, and 
the cell adhesion peptide, KRSR, onto the CA surface are evidence that the material can 
be further improved by the easy covalent addition of useful and relevant biomolecules.   
It is well known that cell adhesion peptides that can preferentially bind certain 
types of cells would be the most useful peptides in biomaterials applications to recruit 
specific cells and decrease unwanted cell adhesion. The increase over a seven day period 
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in osteoblast adhesion to KRSR modified CA compared to unmodified and RGD 
modified CA is the longest time period reported thus far. This is also true for the increase 
in osteoblast adhesion to KRSR modified CA compared to fibroblast adhesion over four 
days.  These results are further evidence that KRSR combined with CA produces an 
osteoblast cell-specific surface that would be useful in bone regeneration. 
The covalent immobilization of vancomycin to the CA surface that remains active 
after autoclave sterilization is significant progress in the search to reduce implant 
associated infections due to biofilm formation.  The covalent linkage allows for smaller 
effective doses of antibiotic and for a local delivery, both of which are important factors 
when fighting bacterial infections. 
The co-immobilization of vancomycin and KRSR shows that two biomolecules can 
be simultaneously attached to a surface using two different linker systems in a minimal 
amount of steps.  The results also show that the order of attachment can make a 
significant difference in the activity of both biomolecules. The ability to immobilize 
multiple biomolecules with independent functions on a biomaterial surface has never 
been shown before and is extremely useful in creating biomaterials for specific tissue 
regenerating applications.  In this case, the addition of the two biomolecules created a CA 
surface that can increase osteoblast adhesion and inhibit bacteria growth.  Both of which 
are necessary for a successful bone regeneration scaffold. 
All of the modification schemes used to modify the CA surface are also applicable 
to any surface that contains reactive hydroxyl and µ-oxo groups.  Many existing metallic 
biomaterials contain these types of functional groups on their surfaces and these 
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modification schemes could easily be applied to improve upon the currently approved 
materials. 
In the future, an in vivo critical size bone defect model is needed to evaluate the 
ability of the doubly modified CA surface to increase bone growth in a physiological 
environment.  Similarly, an implant-associated infection in vivo model is necessary to 
determine the antibacterial activity of the modified scaffolds in a physiological 
environment.  If possible, a combined critical size bone defect and implant associated 
infection model would be the most advantageous to fully evaluate the potential of the 
doubly modified CA surface. 
Future studies to evaluate and improve the osteoinductive, osteointegrative, and 
osteogenic properties of the unmodified and modified CA should also be investigated to 
further optimize the material for use as a bone scaffold. 
 
 
